Antimetastatic Effects of Curcumin in Oral and Gastrointestinal Cancers

Abstract

Gastrointestinal (GI) cancers are known as frequently occurred solid malignant tumors that can cause the high rate mortality in the world. Metastasis is a significant destructive feature of tumoral cells, which directly correlates with decreased prognosis and survival. Curcumin, which is found in turmeric, has been identified as a potent therapeutic natural bioactive compound (Curcuma longa). It has been traditionally applied for centuries to treat different diseases, and it has shown efficacy for its anticancer properties. Numerous studies have revealed that curcumin inhibits migration and metastasis of GI cancer cells by modulating various genes and proteins, i.e., growth factors, inflammatory cytokines and their receptors, different types of enzymes, caspases, cell adhesion molecules, and cell cycle proteins. Herein, we summarized the antimetastatic effects of curcumin in GI cancers, including pancreatic cancer, gastric cancer, colorectal cancer, oral cancer, and esophageal cancer.

Introduction

Various mechanisms are involved in the induction of malignant neoplasms in the gastrointestinal tract (Sharma and Bhatia, 2018). Most of the upper gastrointestinal tract carcinomas are caused by aggregated genetic events and uninterrupted mucosal injury (Sharma and Bhatia, 2018). While pre-existing adenomas are the origin of colorectal carcinomas, typically. Chronic injuries resulted in prolonged-mucosal damages such as inflammatory bowel disease (IBD). It causes a small number of cancers in the lower parts of the gastrointestinal tract (Axelrad et al., 2016). Research on the molecular pathways has led to considerable advances in the understanding of tumor progression processes. For example, detecting different mutations that affect tumor suppressor genes or those involved in DNA repair may be applicable for identifying the patients with heritable cancer risk (Wang et al., 2018). Besides, others show therapeutic indications. A growing number of oncogenic mutations have been recognized in gastrointestinal malignancies, which may be applied or manipulated (Lv, 2017).

Metastasis is disseminating tumoral cells from the original tumor to the primary organ's potential locations or other contiguous and remote organs (Das et al., 2020). As the significant destructive feature of tumoral cells, the incidence of metastasis in various types of cancer directly correlates with decreased prognosis and survival in patients (Deepak et al., 2020). Malignant cells dissemination of primary tumor is the first step for metastasis initiation, intravasation into the blood circulation system is considered the next step, the third step is linked to arrest of tumoral cells in a distant vascular bed, and in the fourth step, cancer cells extravasation into the interstitial tissue of a target organ occurs (Fouani et al., 2017). During the metastasis process and proliferation in a metastatic site, revascularization plays a crucial role in malignant spread, as it supplies the metabolic requirements for the fast duplicating malignant cells (Bielenberg and Zetter, 2015; Luo et al., 2020).

Curcumin or [(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] is a polyphenolic extraction of Curcuma longa species, which is often termed as turmeric (Shafabakhsh et al., 2019; Ashrafizadeh et al., 2020). Curcumin had been used as a traditional Ayurvedic medicine due to its significant anti-inflammatory (Satoskar et al., 1986), antioxidant (Masuda et al., 2001), and antimicrobial (Negi et al., 1999) properties. Currently, curcumin is associated with powerful anticancer properties. Different animal studies have shown that curcumin has important roles in inhibiting primary tumorigenesis in numerous organs as metastatic sites, such as mammary glands (Inano et al., 1999) and gastrointestinal tract (Huang et al., 1994). Some investigations showed that curcumin has potential regulatory effects on the expression of proangiogenic growth factors (6–8). Curcumin inhibits angiogenic activities caused by fibroblast growth factor (bFGF) in rabbit and mouse models (Mohan et al., 2000). It also diminished the vascular endothelial growth factor (VEGF) serum levels in mice models of hepatocellular carcinoma (Yoysungnoen et al., 2006). Interleukin (IL)-1β and monocyte chemotactic protein-1 (MCP-1) are critical inflammatory cytokines in tumorigenesis. Accordingly, some studies demonstrated that these cytokines' expression levels reduced after curcumin intervention (Abe et al., 1999).

The dynamic interplay between neoplastic cells and the immune microenvironment regulates multiple steps in the metastatic process. The tumor-specific immunosuppressive microenvironment serves an important function in tumor tolerance and escapes from immune surveillance leading to tumor progression. Therefore, identifying new drugs or foods that can enhance the tumor immune response is critical to develop improved cancer prevention methods and treatment. Recent studies have also indicated that curcumin can modulate tumor immune responses and remodel the tumor immunosuppressive microenvironment, indicating its potential in the immunotherapy of cancer (Mukherjee et al., 2018; Bahrami et al., 2019a; Pan et al., 2019). Curcumin has antimetastatic activities, modulating T cells, B cells, macrophages, neutrophils, NK cells, dendritic cells and production of cytokines and chemokines. In addition, recent studies have shown that curcumin exerts immunosuppressive effects (Shafabakhsh et al., 2019).

These findings showed that curcumin has crucial roles in the inhibition of angiogenesis and metastasis in GI cancers. Also, both the important events, including angiogenesis and inflammation, have been shown to contribute to metastatic formation and proliferation in GI cancers. Herein, we have summarized antimetastatic effects of curcumin in GI cancers.

Metastasis

“Metastasis” is an important process in which secondary tumors are developed in one of the organs that are separate from the original primary cancer site. Considering its considerable functions in the induction of failures in cancer management and increasing rate of mortality, apoptosis has been poorly understood currently. Although in vivo studies suggested that the percentage of metastases in melanoma cancer patients is <0.1% of tumor cells, but a more significant number of cancerous cells are released in blood circulation in other types of cancer (Luzzi et al., 1998). To metastases progression, tumoral cells must move from their primary tumor site, disperse in blood circulation, tolerate blood vessels' pressure, conform to new cellular settings in a secondary tumor location, and avoid immunological responses (Maitra, 2019; Massagué and Obenauf, 2016). Hanahan and Weinberg (2011) have declared that “invasion and metastasis activation” are signs of tumors. Therefore, metastasis as a major characteristic of cancer malignancies, accession to power from presentation of invasiveness features in surrounding tissue and homing on distant sites. Several factors such as tumor-secreted factors and exosomes dictate metastatic development (Figure 1). Unfortunately, metastasis represents the primary cause of death in a percentage of >90% of cancer patients (Steeg, 2006). Herein, comprehending connections of metastatic processes help us to recognize molecular and cellular targets for designing optimal therapies for suppressing or attenuating metastasis and consequent cancer progression. As mentioned earlier, cancer cell dissemination is the initial step of the metastases processes (Lambert et al., 2017). Chromosome segregation continuous errors during mitosis can lead to chromosomal instability, which is the potential cause in the induction of metastasis cascade (Figure 2). Numerous molecular and cellular factors have roles in invasion and metastasis activation, such as epigenetic factors, adhesive signals of extracellular matrix (ECM) components, ECM mechanical pressures, cell–cell interactions, soluble signals, and the intratumoral microbiota. Rupture of micronuclei via chromosome segregation errors leads to genomic DNA secretion into the cytosol. It functions as a cytosolic DNA-sensing pathways activator (cyclic GMP-AMP synthase–stimulator of interferon (IFN) genes) and finally activation of nuclear factor ?-light-chain-enhancer B (NF-κB) signaling pathway (Bakhoum et al., 2018).

FIGURE 1

FIGURE 2

Various studies have suggested that the primary disseminate nature of tumoral cells can be used as a potent determinant (Tabassum and Polyak, 2015; Gundem et al., 2015). An individual migration pattern of metastatic cancer cells was observed in vivo and in vitro investigations (Clark and Vignjevic, 2015). Inversely, in human cancer patients, the concerted action of a cluster of tumor cells is required for seeding (Cheung and Ewald, 2016). The ability of invasiveness, resistant stress, and dissemination of transformed epithelial cells develop in a trans-differentiation process called epithelial–mesenchymal transition (EMT) (Hanahan and Weinberg, 2011). Immotility and tight bounding together are some of the key features of epithelial cells. Also, epithelial cells are closely allied to the neighboring extracellular matrix (ECM) (Fouad and Aanei, 2017). Through governing reversible biochemical alterations, EMT accounts for permitting a specific epithelial cell for achieving a mesenchymal phenotype that admits significant epithelial–mesenchymal plasticity (Ye and Weinberg, 2015). Epithelial–mesenchymal plasticity is an essential specification for the development and metastasis of cancer cells (Figure 3). There are two main invasion patterns of tumor cells: single-cell dissemination and collective-cell migration. Current understanding of metastatic cell migration has relied primarily on studies on single-cell migration. However, the current paradigm focused on single-cell movements is shifting toward a dogma that collective migration is likely one of the primary modes of migration during metastasis of many solid tumors. Not surprisingly, the mechanics of collective migration differ significantly from single-cell movements (Lintz et al., 2017).

FIGURE 3

Moreover, it has been proved that all of the tumoral cells which originated from the primary site of the tumor have not to function in the contribution of metastasis development. It has been reported that an increased level of asparagine synthetase, which acts as a pivotal metabolic enzyme, is associated with metastasis progression in mouse-bearing breast cancer (Knott et al., 2018). Treatment with ʟ-asparaginase or dietary restriction-mediated decreasing in the level of asparagine has been reported to be an optimal strategy for reducing metastatic spread. Furthermore, recent studies have demonstrated that the availability of asparagine could lead to promoted EMT (Knott et al., 2018). Recently, a pseudo choice between full-mesenchymal phenotypes or full-epithelial in the EMT process has been rejected. At the same time, we have understood that EMT is a program with various transitional stages between the mesenchymal and epithelial phenotypes (Nieto et al., 2016). Various growth factors (Katsuno et al., 2013) and signaling cascades are governing the transition of the stage to each other in the EMT program (Craene and Berx, 2013). To that end, spontaneous EMT is shifting between various intermediate stages and intermediate phenotypes with extended invasive, metastatic, and differentiation features in primary tumor cells (Pastushenko et al., 2018). For observing better effectiveness in circulation and colonization at the secondary site and the consequent progression of metastases, tumor cells must have a combination of mesenchymal and epithelial phenotypes in EMT (Pastushenko et al., 2018). Numerous distinct and common transcriptional factors and signaling pathways regulate different cellular characteristics, chromatin landscapes, and gene expression signatures in various EMT stages (Pastushenko et al., 2018).

Metastasis Induction

Metastasis and Matrix Metalloproteinases

Degrading of basal membrane and extracellular matrix, which is caused by proteolytic agents such as matrix metalloproteinases (MMPs), can lead to peritumoral matrix destruction and subsequent invasive growth pattern (Brooks et al., 2010). To that end, MMP plays a crucial role in the invasion and metastases through entering the lymphatic system and blood circulation and then increasing the dissemination of tumor cells from the primary tumors into the enclosing tissues and secondary tumor sites.

In various in vivo and in vitro experimental studies, the upregulated expression level of MMPs has been correlated with significant growth and proliferation behavior of tumoral cells (Bachmeier et al., 2000a; Bachmeier et al., 2000b; Bachmeier et al., 2001; Murphy and Nagase, 2008). MMPs play pivotal functions in various tumor development features via affecting numerous biological processes. These features include activation of growth factor (Egeblad and Werb, 2002), tumor growth, induction of invasiveness, tumor-related inflammation, revascularization, and metastasis (Han et al., 2001; Philip et al., 2001). Hence, controlling expression levels of MMPs and suppression of its activation can be considered an optimal strategy for the prevention of cancer development.

Gene transcription is the first level that MMP expression inhibition initiates at that level. The promoter regions contribute to encoding the MMP-1, -2, -3, -7, -9, -12, and -13 genes, which are similar to NF-κB elements, carry a proximal activating-protein-1 (AP-1) binding site about 70 base pair 5′ for starting the transcription (Vincenti et al., 1998; Westermarck and Kähäri, 1999; Bond et al., 2001; Vincenti, 2001).

The properties of curcumin on the expression level of MMP and its functions have been investigated in different experimental studies in various kinds of inflammatory diseases and cancer models (Lin et al., 1998; Banerji et al., 2004; Swarnakar et al., 2005; Hong et al., 2006; Mitra et al., 2006; Su et al., 2006; Bachmeier et al., 2007; Shakibaei et al., 2007). By downregulating the expression of AP-1 and NF-κB, curcumin has been demonstrated to be a significant suppressor of MMPs synthesis (Bachmeier et al., 2007). Kim et al. reported that, through suppressing the activation of NF-κB and AP-1, curcumin inhibited the expression of MMP-9 and accompanied cell invasion mediated by12-O-tetradecanoylphorbol-13-acetate treatment (Kim et al., 2012a).

Bachmeier and colleagues demonstrated that the MMP-1 and MMP-2 mRNA expression and protein levels were considerably diminished after treatment with curcumin in breast cancer cells. In contrast, there was no considerable decrease in the expression levels of MMP-3 and -9 (Bachmeier et al., 2007). Furthermore, gelatinolytic activity has been evaluated by zymography, revealed that gelatinases MMP-2 and -9 proteolytic activities, down-regulated after treatment with curcumin.

An in vitro investigation on human fibrosarcoma cells demonstrated that the MMP-2 and MMP-9 expression levels were remarkably suppressed after treatment with three separate curcuminoids (demethoxycurcumin, bisdemethoxycurcumin, and curcumin). In comparison, there were no remarkable properties of the invasiveness of these cells and the urokinase plasmin activator (uPA) (Yodkeeree et al., 2008). To that end, in laryngeal squamous carcinoma cells, curcumin treatment induced significant down-regulatory impacts on the MMP-2, MT1-MMP expression, integrin receptors, and focal adhesion kinase (FAK), which led to a remarkable reduction in the invasiveness features of the tumoral cells. It is essential to state that the expression levels of MT1-MMP, MMP-2, integrin receptors, and FAK were similar to regulated expression levels after drug withdrawal (Mitra et al., 2006). Treatment with curcumin in human colon cancer cells caused a significant up and downregulation of MMP-9 and MMP-2, respectively. But any remarkable effect on the MMP-7 expression has not been observed, as evidenced by protein levels in Western blotting assay (Su et al., 2006). Curcumin treatment caused a noteworthy reduction in MMP-2 and MMP-9 expression, in conjunction with reduced cellular invasion in vitro in prostate cancer cells (DU-145). Besides, curcumin treatment diminished tumorigenicity in a xenograft model (Hong et al., 2006). Fifteen days of intervention with curcumin in a metastatic model of murine melanoma cells B16F10 remarkably decreased MMP-2 activity (Banerji et al., 2004). Besides, curcumin also reduced FAK and MT1-MMP expression. Results showed that even following 28 days, drug withdrawal could not return the MMP-2, MT1-MMP, and FAK expression to control levels. In the same study, curcumin caused a significant reduction in the level of invasiveness and migration and, reversely, promoted apoptosis in vitro (Philip and Kundu, 2003; Philip et al., 2004). In glioma cell lines, curcumin suppressed the TPA-mediated expression level of MMP-1, -3, -9, and -14-related mRNAs (Woo et al., 2005). On the other hand, following the curcumin intervention, the expression of numerous cell survival and proliferative inducer agents, such as cyclin D1, COX-2, IL-6, MMP-9, and Bcl-2, were significantly suppressed in the squamous carcinoma cells of the head and neck (Aggarwal et al., 2004). Following the curcumin treatment in a xenograft model of prostatic cancer, MMP-9 and MMP-2 expression remarkably decreased. Furthermore, a remarkable inhibitory effect on the invasion ability of the tumoral cells was observed in vitro. In this study, tumor volume, several metastatic nodules in the animal model, and the MP-2 and MMP-9 activity in the tumor-bearing site reduced significantly (Hong et al., 2006). Along with inhibition of ER downstream pS2 and TGFβ target genes, curcumin treatment in MCF-7 cell lines of breast cancer and estrogen presence significantly suppressed the estrogen receptor (ER) expression. By this study, curcumin treatment also showed significant down-regulatory effects on MMP-2 expression, while TIMP-1 (tissue inhibitor of metalloproteinase) expression was markedly upregulated after curcumin treatment (Shao et al., 2002).

Besides, different studies also have evaluated the properties of curcumin on the invasiveness of lung cancer models: through suppression of MMP-2, -9, and VEGF expression, curcumin significantly decreased migration features and invasiveness of A549 cell line in a time-dose-dependent manner (Lin et al., 2009). The above-mentioned effects were also observed in an in vivo model by affecting the expression of the 801D cell. Inhibition of the Rac-dependent pathway by curcumin caused a remarkable decrease in the MMP-2 and -9 expression levels (Chen et al., 2014).

Overall, considering slight differences in the efficiency of curcumin in the inhibition of MMPs in some cell lines or studies, it seems that curcumin has significant modulatory effects in virtually all of MMPs. These minor discrepancies may result from slight differences in curcumin-related responsivity and partial resistance of some cell lines (Bachmeier et al., 2009). Furthermore, it is evident that curcumin considerably plays pivotal functions in inhibiting degradation in some of the extracellular matrix and basal membrane components. These effects are due to its potential action in regulating MMP/TIMP activity and expression, which was led to the significant impacts on the reversion of tumor invasion and growth.

Metastasis and RAF/MEK/RAS/ERK Signaling Pathway

The RAF/MEK/RAS/ERK signaling pathway is the primary modulator of different cellular processes. This signaling pathway contributes to the modulation of cell differentiation, proliferation, survival, and motility. It provides the transduction of signals from the cell surface to the nucleus and cytoplasm as well. Moreover, abnormal regulation of this signaling pathway is a potential reason for the initiation and progression of tumoral cells. Cell surface receptors-mediated activation of small GTPase rat sarcoma oncogene (RAS) homolog leads to binding binds and the consequent rapid activation of accelerated fibrosarcoma kinase (RAF). H-, K-, and N-RAS have been considered the most related members of the RAS family, clinically. RAF has three isoforms, including a-, b-, c-RAF, considering the major role b-RAF in tumorigenesis. RAF contributes to phosphorylation of MAPK and ERK kinase (MEK), which for its parts has crucial roles in the mitogen-activated protein kinases (MAPKs) activation. The primary MAPKs members have been reported as extracellular signal-regulated kinases (ERK) 1 and 2. Considering their important roles, ERK-1/-2 with a variety of substrates also have been considered major effectors of this pathway (Figure 4).

FIGURE 4

Activating RAS or b-RAF mutations has been significantly associated with higher RAS/RAF/MEK/ERK signaling activation. Moreover, various studies have demonstrated that K-RAS is the principal mutated RAS gene in the pancreas, lung, and colon adenocarcinoma samples (Bos, 1989; Campbell and Der, 2004). Besides, some of the receptor tyrosine kinases, such as EGFR, were correlated to the activation of RAS. Mutational activation or overexpressed level of EGFR has been associated with lower cancer prognosis. It is also associated with upregulation of signaling pathways, including RAS/RAF/MEK/ERK, PI3K/Akt/mTOR, protein kinase C (PKC), phospholipase D signal transducer, and activator of transcription (STAT) (Roberts and Der, 2007). Curcumin has been shown to exhibit anticancer effects by interfering with signaling pathways associated with the initiation, promotion, and progression of multistage carcinogenesis. Curcumin inhibits the ERK signaling pathway, thus blocking the cell cycle and downregulates the expression of Bcl-2, concomitantly inhibiting cell proliferation and inducing apoptosis (Zhu et al., 2016).

Metastasis and Wnt Signaling Pathway

Wnt signaling pathway plays pivotal functions regulating cell polarity, cell proliferation, and cell fate determination during embryonic development. It has been shown that in the absence of the Wnt signaling pathway, the multiprotein complex has the responsibility of regulating intracellular β-catenin levels. Investigations have displayed that adenomatous polyposis coli protein (APC) as a tumor suppressor, casein kinase 1 (CK1), glycogen synthase kinase-3β (GSK3β), and the scaffolding protein Axin are involved in the multiprotein complex structure. It has been reported that Cytoplasmic β-catenin is an essential target for induction of ubiquitination and proteasomal degradation by the destruction of complex-mediated binding and phosphorylating. As this elimination process continues, β-catenin cannot reach the nucleus any longer. Another important family of transcription factors is the DNA-bound T-cell factor/lymphoid enhancer factor (TCF/LEF), which has been suggested to be one of the principal regulators of β-catenin gene expression. Lacking the nuclear β-catenin, through inactivating Groucho/TLE, as transcriptional corepressors by binding to them, TCF/LEF contributes to suppressing gene expression. Wnt has a crucial role in Wnt/β-catenin pathway activation by binding its ligands to its co-receptor–low-density lipoprotein receptor-related proteins (LRP)—and also the Frizzled receptor. As a result, these receptors will be activated. Activation of Wnt/β-catenin pathway significantly hinders the destruction complex, and finally can lead to enhanced aggregation and nucleic translocation of β-catenin. It has been proved that, through binding to TCF/LEF and accompanied inactivation of them, and via dislocating the Groucho/TLE, transcriptional co-repressors, β-catenin activates Wnt target gene expression in the nucleus (Figure 5) (Daniels and Weis, 2005; Fodde and Brabletz, 2007). Curcumin inhibits tumor epithelial–mesenchymal transition by downregulating the Wnt signaling pathway and upregulating NKD2 expression in cancer cells (Zhang et al., 2016). Furthermore, curcumin suppresses cancer cell migration by inhibiting the Wnt signaling pathway (Kim et al., 2013).

FIGURE 5

Curcumin and Metastasis in Gastrointestinal

Regulation of Metastasis in Pancreatic Cancer by Curcumin

Curcumin-mediated effects on metastasis in pancreatic cancer cells are associated with their properties on various heterotypic cells—these cells, including endothelial cells, macrophages, cancer-associated fibroblasts (CAFs). CAFs have been implicated in different malignancies, such as pancreatic ductal adenocarcinoma (PDAC), breast cancer, and gastric carcinoma (Kasashima et al., 2014; Sun et al., 2014). By targeting numerous cellular events in cancerous cells such as cell viability, tumor growth, metastasis, revascularization, immune surveillance, and CAFs, curcumin plays a crucial role in regulating tumor behavior (Lunardi et al., 2014). It has been reported that the expression level of α-smooth muscle actin (α-SMA) and vimentin is significantly correlated with the process of attaining an activated phenotype by CAFs. Besides, for transforming into fibroblast-like cells, tumoral cells can potentially make use of EMT (Kalluri and Zeisberg, 2006). EMT has been introduced to be a transcriptional and epigenetic process in which some of the mesenchymal features, including enhanced motility and decreased cellular junctions, can be acquired by epithelial cells, which have important roles in the dissemination of primary tumor sites and cancer seeding at distant organs (Thiery, 2002; Friedl, 2004). In addition to CAFs capabilities for affecting the EMT of cancer cells, it has been proven that the expression of fibroblast-like cancer cells is considerably associated with higher invasion and metastatic features. Reduced expression of E-cadherin, which has been associated with tumor progression and development, is an important sign of EMT (Cowin et al., 2005; Christofori, 2006; Francí et al., 2006).

Wang and colleagues theorized that CAFs might be a possible target of curcumin for inhibiting pancreatic cancer cells’ metastases (Wang et al., 2017). Their results have shown that curcumin significantly suppressed the CAF-induced promotion of metastasis and migration abilities in pancreatic cancer cells. Overall, by decreasing the mesenchymal features of CAFs, data provided substantial evidence that curcumin suppressed pancreatic cancer cells’ metastasis and migration characteristics. It resulted in the reversed mediation of EMT phenotypes in pancreatic cancer cells (Wang et al., 2017).

Hypoxia is low oxygen tension traditionally found in solid tumors, which is considerably associated with decreased prognosis in cancer patients (Lei et al., 2013; Chang and Erler, 2014). Results have shown that tumor hypoxia-induced behavior of tumoral cells is significantly correlated with promoted invasion, angiogenesis, and metastasis in distant tumor sites (Chang and Erler, 2014). Hypoxia-inducible factor-1 (HIF-1) is a member of the primary helix-loop-helix-periodic acid-Schiff domain transcription factor family and has been implicated in several types of solid tumors, such as pancreatic cancer. HIF-1haskey functions in the mediation of hypoxia-induced cellular responses (Lei et al., 2013). In their study, Sun et al. (2013) demonstrated that via inhibiting the Hh signaling pathway, the progression of pancreatic cancer was diminished after curcumin intervention. As a crucial pathway in tumorigenesis, the Hh signaling pathway has been shown to be implicated in pancreatic cancer samples while it is quiescent in adult pancreas cells in a normal situation (Lei et al., 2013). In a recent study, Lei et al. have shown that hypoxia-mediated invasiveness and occurrence of EMT is closely associated with the Hedgehog signaling pathway (Lei et al., 2013). Cao and colleagues hypothesized that curcumin is a prominent inhibitor for preventing hypoxia-induced invasiveness, proliferation, metastasis, and EMT progression in pancreatic cancer. Besides, they have been shown that curcumin strongly suppressed hypoxia-induced activation of Hedgehog signaling pathway. It suggested that curcumin may be a potential novel treatment for optimizing current therapeutic treatments against pancreatic cancer (Cao et al., 2016a). The results reported that in addition to its properties against hypoxia-mediated activation of Hedgehog signaling pathway, cell migration, proliferation, and invasiveness of pancreatic cancer, curcumin also mediated the EMT-related agent’s expression including vimentin, E-cadherin, and N-cadherin. Taken together, Cao and colleagues have demonstrated that via suppressing the Hh signaling pathway, curcumin plays critical roles for the inhibition of hypoxia-mediated metastasis of pancreatic cancer (Cao et al., 2016a).

Hydrogen peroxide (H2O2) and superoxide anion as reactive oxygen species (ROS) are some chemically oxygen-derived reactive agents. They are generated by the mitochondrial respiratory chain. In various studies, the state of intracellular redox has been correlated with cellular signaling transduction, and regulation of multiple intracellular events (Lee and Kang, 2013). Despite their significant roles for suppressing cancer cells, via affecting cell viability, proliferation, invasion, and metastasis, sublethal concentrations production of ROS has been associated with tumor progression (Nishikawa et al., 2009). For example, Nishikawa et al. showed that sublethal concentrations of H2O2 (0–200 µM) resulted in pancreatic cancer development in a dose-dependent manner. In contrast, > 200 µM concentrations of H2O2 were cytotoxic for cancerous cells (Li et al., 2015).

Recently, a study demonstrated that curcumin had strong protective properties against the EMT process in the prostate cancer cells. Curcumin abrogated CAF-induced invasion and EMT, and inhibited ROS production and CXCR4 and IL-6 receptor expression in prostate cancer cells. These effects were mediated by inhibiting MAOA/mTOR/HIF-1α signaling. It was found that this protective effect correlated with MAOA/mTOR/HIF-1α signaling pathway-induced inhibition of CAFs-mediated ROS generation (Du et al., 2015). As crucial downstream signaling cascades of ROSs, MAPK signaling pathways have been demonstrated to participate in tumor progression (Wu et al., 2008). P38 MAPK, extracellular signal-regulated kinase (ERK), and c-jun NH-2 terminal kinase (JNK) are the most critical MAPK family members. Li et al. have declared that via activating p38 MAPK and ERK signaling pathways, moderate amounts of H2O2 are associated with promoted pancreatic cancer metastasis and invasion (Li et al., 2015).

Cao et al. showed that curcumin intervention in Panc-1 and BxPC-3 pancreatic cancer cells reversely regulated the cancer invasion, migration, and MMP-2 expression. Besides, H2O2-mediated upregulation of phosphorylated ERK and phosphorylated NF-κB was decreased after NAC, curcumin, and PD 98059 treatment (an ERK inhibitor). Considering this valuable information, it can be concluded that curcumin inhibited pancreatic cancer cell migration and invasiveness via inhibiting the ROS/ERK/NF-κB signaling pathway. Furthermore, this study suggested that curcumin application might be a possible drug target for upregulating pancreatic cancer migration (Cao et al., 2016b). Table 1 lists various studies on antimetastatic effects in pancreatic cancer. Figure 6 illustrates the effects of curcumin on metastasis in GI cancers.

FIGURE 6

Regulation of Metastasis in Gastric Cancer by Curcumin

It has been demonstrated that high mobility group box 1 (HMGB1), as an essential nuclear and extracellular protein, is a crucial mediator in various pathologic and physiologic situations such as inflammation, immune response, and cancer. HMGB1 is also a diagnostic biomarker for the early stages of gastric cancer (Chung et al., 2009). Curcumin treatment in human endothelial cells caused considerable down-regulatory properties on the expression of the cell surface receptor of HMGB1 (Kim et al., 2011). Studies have reported that HMGB1 expression is highly increased in esophageal squamous cell carcinoma (ESCC). HMGB1 has a crucial role in promoting lymphangiogenesis by regulating vascular endothelial growth factors (VEGF)-C. Lymph node metastasis has been considered one of the critical determinants of progression in gastric cancer patients. Studies have declared that HMGB1 expression is associated with tumor lymphangiogenesis and new lymphatic vessel formation (Tawada et al., 2012). Curcumin treatment resulted in VEGF receptors’ downregulation, including (VEGFR-2/3) and lymphangiogenic VEGF-C (Da et al., 2015). HMGB1 and VEGF-D are involved in tumor lymphangiogenesis, and VEGF-C and VEGF-D are also essential members of the VEGF family.

In a recent study, Da and colleagues hypothesized that by suppression of HMGB1/VEGF-D signaling, curcumin might have potential anti-lymphangiogenesis properties. Therefore, it can be applied as a potential treatment in patients with gastric cancer (Da et al., 2019). Results have demonstrated that curcumin treatment in AGS and SGC-7901 gastric cancer cells caused a significant cell viability reduction through activating caspase-3. In contrast, it resulted in an apoptosis increase in a concentration-dependent manner. Besides, curcumin intervention remarkably eliminated the HMGB1 and VEGF-D expression levels. Considering their findings, they have suggested that curcumin might be an anti-lymphangiogenesis agent in the treatment of gastric cancer by inhibiting HMGB1/VEGF-D signaling (Da et al., 2019).

Late-stage diagnosis, which is seen in most gastric cancer patients, causes poor prognosis and therapeutic outcome. This problem results in tumor cell dissemination into circulation and distant organs as circulating tumor cells (CTCs), which leads to cancer seeding, and formation of a distal tumor, especially in hepatic tissue (Saito et al., 2013; Hatakeyama et al., 2015; Xia et al., 2015). In addition to their presence in blood circulation, CTCs have been identified with a number of specific cell surface markers. Among them, CXCR4, which is known as the stromal cell-derived factor-1 (SDF-1) receptor, has been characterized by different cancer types (Reckamp et al., 2009; Franco et al., 2012; Mego et al., 2016). In their previous study, Zhu et al. have declared that CD90⁺ and CXCR4+ hepatocellular carcinoma (HCC) cells may be CTCs. Therefore, selective inhibition of CD90⁺ and CXCR4+ cells, resulting in reduced cancer metastasis, may provide significant improvements in the current therapeutic approaches in HCC patients (Zhu et al., 2015).

Gu et al. have evaluated the antimetastatic capabilities of curcumin in the reduction of tumor formation in liver in mice-bearing proximal gastric carcinoma (PGC) (Gu et al., 2019). Results showed that formation of hepatic tumor and presence of CTCs were considerably reduced after curcumin treatment. Furthermore, treatment with curcumin in PGCs in vivo and in vitro downregulated the CXCR4 expression, and hence by inhibiting the SDF-1/CXCR4 signaling pathway, suppressed metastasis of PGC (Gu et al., 2019).

By suppressing the activity of MMP-2, curcumin administration has been associated with inhibiting cancer progression (Mitra et al., 2006; Lee et al., 2015a; Liu et al., 2017). Moreover, due to its low solubility, bioavailability and efficacy of curcumin is decreased. Various in vivo investigations have demonstrated that induction of structural modifications in the β-diketone moiety, aromatic rings, or the flanking double bonds coupled with the β-diketone moiety of curcumin may be an optimal strategy for improving its bioavailability and anticancer activities. Selected CH-5 (4,4′-[(2-Oxo-1,3-cyclohexanediylidene)-di(E) methylylidene]dibenzonitrile) and monoketone curcumin analogs have been screened to be evaluated for their anticancer properties in numerous tumor cell lines (Lima et al., 2018).

Silva and colleagues investigated the antimetastatic properties of CH-5 in human HGC-27 gastric cancer cell line (Silva et al., 2018). Initially, they have observed cell viability was decreased, while apoptosis was increased in a dose-dependent way. Additionally, through decreased expression and collagenase activity of MMP-2, a remarkable decrease in the invasiveness and migration of HGC-27 cells was observed after CH-5 treatment. Herein, via the upregulation of apoptosis and the downregulation of invasion and migration, CH-5 treatment in gastric cancer cells showed anticancer properties. It implies that the application of CH-5 molecule can be considered an optimal antimetastatic medicine for the prevention of gastric cancer development (Silva et al., 2018). Table 2 lists various studies on antimetastatic effects of in gastric cancer.

Regulation of Metastasis in Colorectal Cancer by Curcumin

Cancer stem cells (CSCs) are a small subpopulation of immortal cells. They are essential agents in chemoresistance, tumor invasion, and relapse. CSCs have crucial functions in metastasis induction, which is considered the leading factor of cancer-related mortalities (Muñoz et al., 2012). Numerous studies have shown that curcumin targeted Wnt/β-catenin, Notch, and Sonic Hedgehog (SHH) signaling pathways. These are involved in the self-renewal of tumoral cells, targeting CSCs to prevent cancer invasion (Takebe et al., 2015). Some investigators believe the anti-inflammatory properties of curcumin are additionally engaged in its antimetastatic characteristics.

It has been demonstrated that overexpression of insulin-like growth factor-1 (IGF-1) and insulin is an essential agent in cancer progression and metastasis (Adachi et al., 2002; Sarfstein et al., 2010; Liu et al., 2011; Orrù and Nigro, 2017). There is a lot of resemblance in action between insulin and IGF-1 signaling; herein, there is a possibility of recruitment of each other’s receptors by their ligands (Panda et al., 2013). Besides, through affecting similar mechanisms, both these receptors play crucial roles in the activation of similar intracellular pathways (Han et al., 2017). Inhibition of IGF-1 in some specific cancer types, such as pancreatic carcinomas, led to decreased cancer growth and metastasis. In contrast, the role of insulin receptor downregulation in the suppression of cancer development has not yet been fully understood (Subramani et al., 2014). Larsson and colleagues demonstrated that hyperinsulinemia is positively associated with progression of colorectal cancer in diabetic patients (Larsson et al., 2005). They also reported that through modulating mitogen-activated protein kinase (MAPK) and IRS1/phosphoinositide 3-kinase (PI3K)/Akt signaling pathways, insulin significantly increases the mRNA expression of (MMP-2) in HCT-116 human colorectal cells (Larsson et al., 2005).

Various investigations have suggested that anti-inflammatory properties of curcumin are involved into its inhibitory effects on migration of tumoral cells. Insulin and IGF-1 receptors and signaling pathways were regulated by curcumin. As an essential pathway, insulin signaling participates in tumor progression and initiation. To that end, Hosseini and colleagues hypothesized that via downregulating insulin and IGF-1 receptors, curcumin could show its antimetastatic properties (Hosseini et al., 2019). In their study, the effects of curcumin treatment were measured in 5-fluorouracil (5-FU)-treated viable resistant SW480 colorectal cells. Their results showed that the expression of avian myelocytomatosis virus oncogene cellular homolog (MYC), IGF-1 receptors, and insulin was remarkably decreased after treatment with curcumin. Therefore, insulin and IGF-1 receptors downregulation in chemoresistant colorectal cancer cells caused a greater reduction in the migration and proliferation of tumoral cells (Hosseini et al., 2019).

Application of curcumin in combination with different medicines including 5-FU (Toden et al., 2015), to lfenamic acid (Sankpal et al., 2016), and ulinastatin (Shen et al., 2014) can make its utilization more effective, reverse chemoresistance, inhibit cell growth, and metastasis. More than 300 numerous constituents, including free arabinose (1%), curcumin (3–5%), essential oil (2–7%), and acid glycans named ukonan, were extracted from turmeric, which is known as the significant source of curcumin (Kim et al., 2012b). Moreover, various studies demonstrated that besides curcumin, different components in turmeric have been introduced to be more potent for displaying antitumor activities, and can be used as potential enhancer of curcumin bioavailability (Anand et al., 2007; Kim et al., 2012b). Yue et al. demonstrated that the accumulation of curcumin within colonic cells was increased in the presence of turmerones in the extract of turmeric (Yue et al., 2012). Furthermore, curcumin plus turmerones or curcumin in the extract of turmeric can promote the antitumor properties in the colorectal cancer model in vivo (Yue et al., 2016). Thus far, a few investigations evaluated the turmeric extract antimetastatic properties on colorectal cancer. According to Kim et al., CXC motif receptor 4 (CXCR4) expression, as a chemokine receptor that has a role in metastasis in vitro, was inhibited after turmeric extract treatment (Kim et al., 2012b).

Using an aggressive orthotopic CRC model with spontaneous metastasis, Li et al. evaluated antimetastatic and antitumor properties of turmeric extract and first-line chemotherapeutics (FOLFOX) (134). Their results showed turmeric extract significantly induced a cytotoxic effect, suppressed colony formation, reduced cell motility, migration, and EMT in murine colorectal cancer cells. Turmeric extract showed all these functions using various signaling pathways such as cofilin, ERK, FAK/p-Src, STAT3, and AKT. Besides, in vivo treatment with turmeric extract (200 mg/kg) caused a great reduction burden of a colon tumor, and suppressed hepatic and lung metastasis. Also, turmeric extract treatment significantly promoted immune response via stimulating T cell, altered tumor microenvironment, and displayed antimetastatic properties. For evaluating its antitumoral and antimetastatic properties, turmeric extract was applied for the first time in vivo and in vitro. These results suggested that turmeric extract can be used as an essential factor for the treatment or prevention of metastasis in colorectal cancer patients (Li et al., 2018b).

As mentioned earlier, the poor water solubility of curcumin has limited its bioavailability after oral intake and therefore, correlated with low efficacy of therapeutic usage of this compound (Wang et al., 1997; Aggarwal et al., 2007). For overcoming pharmacokinetic and bioavailability restrictions of curcumin's oral administration, investigators have formulated a curcumin liposome for intravenous application and introduced an optimal drug delivery strategy (Li et al., 2005; Li et al., 2007; Mach et al., 2009; Helson et al., 2012; Ranjan et al., 2013; Storka et al., 2015). Different studies evaluated the efficacy of liposomal curcumin anticancer activities in pancreatic cell lines (MiaPaCa-2 or BxPC-3) xenograft models (Li et al., 2005; Mach et al., 2009; Ranjan et al., 2013). Two and eighth after liposomal curcumin constant infusions in beagle dogs, Helson et al. evaluated curcumin and its active metabolite tetrahydrocurcumin pharmacokinetics, organ, and tissue distribution. Results demonstrated that 2h infusions caused greater curcumin and tetrahydrocurcumin plasma concentrations compared with 8h infusions (Helson et al., 2012), although after the 8h infusions, organ and tissue curcumin and THC distributions were overall higher than 2 h infusions (Matabudul et al., 2012). Curcumin liposomes were tested in a placebo-controlled, randomized, dose-escalation, double-blind study in 49 healthy female and male subjects. Volunteers received an individual IV dose of curcumin liposomes (10–400 mg/m²; n = 2–6 per group, total n = 39) or placebo (n = 10) for 2 h. It was tolerated well, but at dosages ≥120 mg/m², a transient red blood cell echinocyte formation occurred with both liposomes and curcumin. Besides, the mean cellular volume was increased (Storka et al., 2015).

In a study, tolerability and safety of increasing concentrations of liposomal curcumin were investigated in metastatic cancer patients (Greil et al., 2018). Curcumin pharmacokinetics and anticancer activities were investigated as secondary aims in different studies. This clinical trial was conducted as a phase I, open-label study, and single-center. The liposomal curcumin intravenous infusion was performed weekly in patients with metastatic tumors for 8 weeks. Initiate dose was 100 mg/m² over 8 h, following continuous increasing concentrations, the dose raised to 300 mg/m² over 6 h. At 100–300 mg/m² concentrations over 8 h, no dose-limiting toxicity was reported in 26 subjects. While hemolysis was developed in one of the patients who received 300 mg/m² over 6 h, furthermore in three patients who received the same concentrations hemoglobin was decreased> 2 g/dl. Pharmacokinetic analyses demonstrated that after the infusion, plasma concentrations of curcumin were decreased to undetectable levels. Based on RECIST V1.1, curcumin did not show antitumor activities. Transient clinical benefit and tumor marker responses improved significantly in two subjects. The maximum tolerated concentration of liposomal curcumin was 300 mg/m² over 6 h in pretreated patients, and therefore, starting with this dose is suggested for performing anticancer clinical trials (Greil et al., 2018). Table 3 lists various studies on antimetastatic effects in colorectal cancer.

Regulation of Metastasis in Oral Cancer by Curcumin

Slug, Twist, and Snail transcription factors have been introduced as direct suppressors of E-cadherin through interacting between their COOH-terminal with a 5′-CACCTG-3′ sequence in the promoter of E-cadherin (Yang et al., 2004). Various studies have reported that numerous EMT modulators, including Twist, Slug, E-cadherin, and Snail, have pivotal functions in inhibiting cancer invasion and metastatic capabilities. Through decreasing the level of E-cadherin expression, overexpression of Snail or Twist has been reported to be an essential agent for induction of tumor progression, further aberrant regulation of Snail or Twist has also been demonstrated in different types of epithelial tumors, such as gastric (Rosivatz et al., 2002), prostate (Yuen et al., 2007), breast (Martin et al., 2005), head and neck cancer (Yang et al., 2008). Emerging evidence has shown that E-cadherin downregulation is reversely connected with general survival in patients with different epithelial tumors (Richmond et al., 1997; Zhou et al., 2002; Faleiro-Rodrigues et al., 2004; Tseng et al., 2010; Huber et al., 2011). For example, Fan et al. reported expression levels of Snail and Twist were upregulated. In contrast, E-cadherin expression level was downregulated in oral squamous cell carcinoma (OSCC) patients. Besides, E-cadherin lower expression has been introduced to be an individual prognostic marker in patients with OSCC (Fan et al., 2013).

Lee et al. evaluated curcumin antiinvasive properties on the level of MMPs expression and EMT modulators in OSCC SCC-25 cell line (Lee et al., 2015a). Their results demonstrated that MMP-2 and MMP-9 expression significantly decreased, and hence, invasiveness of oral cancer cells was inhibited after curcumin treatment. Curcumin strongly regulated the expression level of EMT-related factors, including Twist, Snail, and E-cadherin. Besides, curcumin treatment upregulated the p53 expression level, which has been demonstrated to be a crucial factor for repressing EMT. Throughout, it can be said that curcumin has critical functions for preventing cancer development, invasion, and metastasis in oral cancer (Lee et al., 2015a).

Epidermal growth factor receptor (EGFR) is a transmembrane protein with 170-kDa molecular weight, and ErbB family member belongs to receptor tyrosine kinases. It has an extracellular ligand-binding, a transmembrane, and an intracellular domain, which have been reported to be associated with tyrosine kinase activity. Binding of ErbB to epidermal growth factor (EGF) as its primary ligand resulted in the EGFR-mediated formation of heterodimers or homodimers with other ErbB protein family members, including ErbB2, ErbB3, and ErbB4. This causes autophosphorylation, which led to the downstream signaling activation, including MAPK/Ras/Raf/ERK, JAK2/STAT3, and PI3K/Akt/mTOR pathways. These signaling pathways have crucial roles in regulating cancer cell proliferation, differentiation, invasion, and migration (Yarden and Sliwkowski, 2001). Studies have shown that activity and upregulation of EGFR are strongly related to increased tumor invasiveness, multiplication, and metastasis (Doumiati et al., 2012; Lin et al., 2014a). Poor prognosis and inadequate responses to chemotherapy have been observed in positive pEGFR tumors (Aquino et al., 2012). Hence, EGFR has been introduced as an essential anticancer drug target (Rabinowits and Haddad, 2012). Classic EGFR inhibitors have been divided into two major categories, including anti-EGFRs monoclonal antibodies and cetuximab, panitumumab, and trastuzumab are anti-EGFRs monoclonal antibodies, while gefitinib, erlotinib, and lapatinib are categorized as tyrosine kinases inhibitors. Currently, the mentioned drugs are used for the treatment of some epithelium-originated carcinomas, such as colorectal (Soeda et al., 2014), head and neck (Maseki et al., 2013), lung (Sgambato et al., 2014), and breast cancer (Nechushtan et al., 2014). Moreover, because of their extended side effects and chemoresistance, the application of these inhibitors has been very limited in treating most patients with cancer.

Through decreasing Egr-1 trans-activation activities, it has been shown that curcumin inhibited the EGFR-mediated growth of human colon cancer cells (Chen et al., 2006). Furthermore, via repressing EGFR expression, cell apoptosis was significantly promoted in breast cancer cells after curcumin treatment (Sun et al., 2012).

Zhen et al. studied the effectiveness of curcumin on invasion and proliferation in SCC-25 cell lines (Zhen et al., 2014). Based on their results, considerable inhibitory effects were observed from curcumin on the SCC-25 cells’ proliferation. Furthermore, curcumin caused the arrest of the cell cycle in the G2/M phase in a dose-dependent manner. Curcumin downregulated the MMP-2, MMP-9, uPA, and uPAR expression, which led to the inhibited invasion of SCC-25 cells. Curcumin downregulated the MMP-9, MMP-2, uPAR, and uPA expression, which led to the inhibited invasion of SCC-25 cells. It has also been revealed that curcumin regulated Akt, ERK1/2, and STAT3 as downstream signaling targets of p-EGFR and EGFR. Besides, as the most important finding of their study, EGF-triggered EGFR phosphorylation and EGF-mediated invasion of SCC-25 cells were suppressed after treatment with curcumin (Zhen et al., 2014).

In various cancer types, hepatocyte growth factor (HGF) and c-Met, its receptor, have been explained to be implicated in the EMT program (Huang et al., 2019). Remarkably, emerging evidence has shown that the HGF/c-Met signaling pathway activation promoted cancer cell migration and invasiveness. Chemopreventive and antitumoral activities of Curcumin have been comprehensively investigated in colorectal cancer (Ismail and Othman, 2019; Wong et al., 2019). Moreover, curcumin has been introduced to be a prominent EMT suppressor in various cancers (Jiao et al., 2016; Liang et al., 2017; Wang et al., 2017; Bahrami et al., 2019b).

In a study, Ohnishi et al. studied the potential impacts of curcumin on HGF-induced EMT in OSCC (Ohnishi et al., 2020). They reported that via activating HGF receptor c-Met, and downstream ERK pathway in HSC4 and Ca9-22 OSCC cell lines, the HGF signaling pathway induced EMT process. Furthermore, via repressing c-Met, HGF-mediated EMT and cell motility were inhibited by curcumin treatment in HSC-4 and Ca9-22 cells. Through downregulating the expression levels of phosphorylated c-Met, and ERK, curcumin effectively inhibited the HGF-triggered upregulation of vimentin. Taking everything into account, the findings of the reviewed investigation demonstrated that possibly by inhibiting c-Met expression, curcumin has pivotal roles in reversed regulating of HGF-induced EMT in oral cancer cells (Ohnishi et al., 2020). Table 4 lists various studies on antimetastatic effects in oral cancer.

Regulation of Metastasis in Esophageal Cancer by Curcumin

As an important member of the CXC subfamily, stromal cell-derived factor 1a (SDF-1a) interacts with the C-X-C chemokine receptor type 4 (CXCR4), seven-transmembrane G protein-coupled receptor (7TMGPCR). It is also a principal agent in the induction of metastasis and invasion in cancer cells (Vandercappellen et al., 2008). Various in vivo studies have shown that SDF-1a is a key agent for triggering migration and metastasis in breast cancer cells (Müller et al., 2001). Moreover, suppression of CXCR4 gene expression mediated by Short hairpin RNA (shRNA) significantly inhibited cell proliferation of esophageal carcinoma (EC). Upregulation of CXCR4 has been reported to be related to poor prognosis, poor clinical outcomes, and raised metastatic features in EC cells (Kaifi et al., 2005).

Lipid rafts are plasma membrane firmly packed microdomains that consist of dynamic assemblies of cholesterol, glycosphingolipid, and proteins. The rafts can affect signal transduction via the recruitment of membrane-associated protein kinases (Zajchowski and Robbins, 2002). The interaction between the growth factors and their receptors plays a critical role in specific adapter proteins and protein kinases translocation to lipid rafts. It provides essential signals for the regulation of cell proliferation (Pike, 2005). Numerous authors demonstrate that the CXCR4 connection with lipid rafts is involved in effective signaling processes (Chinni et al., 2008; Altenburg and Siddiqui, 2009). Ectopic expression of a CXCR4-GFP fusion protein in CXCR4-deficient human hematopoietic progenitor cell lines showed that lipid rafts are crucial in the SDF-1a-induced CXCR4 signaling and surface expression (van Buul et al., 2003).

The colocalization of Rho GTP-binding protein Rac1 and CXCR4 in lipid rafts resulted in increased activation of Rac1 GTPase. It also led to the sensitivity of hematopoietic cells to SDF-1α (Wysoczynski et al., 2005). SDF-1a/CXCR4 axis-mediated cell migration needs the activation of phosphatidylinositol 3- kinase (PI3K)/protein kinase B (Akt) in breast cancer cells (Lee et al., 2004). Numerous investigations demonstrated that hormones, growth factors, and cytokines stimulated the MMP-2 expression via nuclear factor-kappaB (NF-kB) activation (Han et al., 2001; Philip et al., 2004). NF-kB transcription factor constitutive activation in EC has been related to metastatic ability and chemotherapy resistance (Izzo et al., 2006). Besides, active Rac1 (GTP bound Rac1; GTP-Rac1) is required for collagen-mediated MMP-2 activation (Zhuge and Xu, 2001).

Lin et al. investigated these features by evaluating the CXCR4 suppression effects along with a CXCR4-neutralizing antibody and the CXCR4-specific inhibitor AMD3100 treatments (Lin et al., 2014b). Curcumin prevents SDF-1α-mediated cell migration, cell surface localization of CXCR4 at lipid rafts, the activity of matrix metalloproteinase-2 (MMP-2) promoter, and also signaling of lipid raft-related ras-related C3 botulinum toxin substrate 1 (Rac1)/phosphatidylinositol 3-kinase (PI3K) p85α/Akt. Furthermore, curcumin inhibits SDF-1α-mediated cell metastasis by knockdown of the signaling complex of Rac1-PI3K at lipid rafts but did not abolish lipid raft generation. Researchers also explain that the decreasing lipid raft-related Rac1 activity by curcumin was the requirement for preventing cell surface localization of CXCR4 at lipid rafts, SDF-1α-mediated PI3K/Akt/NF-κB activation, cell invasion, and MMP-2 promoter activity. Overall, their findings displayed that curcumin hinders SDF-1α-mediated EC cell invasion by suppressing the lipid raft formation-related Rac1-PI3K-Akt signaling complex, MP-2 promoter activity, likely through the inhibition of Rac1 activity, and the cell surface localization of CXCR4 with lipid rafts (Lin et al., 2014b).

Conclusion

For centuries, curcumin has been widely used as a dietary spice, and contemporary research studies have confirmed its efficacy in cancer therapy. Anticancer effects are the most pivotal properties of curcumin, which affect the different stages of cancer progression, including cancer cell formation, proliferation, and tumor invasion. According to extensive research, curcumin can suppress metastasis in GI cancers via regulating various signaling pathways. Curcumin has a crucial function in metastasis prevention by several mechanisms, including preventing transcription factors as well as their signaling pathways (e.g., NF-κB, STAT3, AP-1), multiple proteases (e.g., MMPs, uPA), inflammatory cytokines (e.g., CXCL1, IL-6, CXCL2, IL-8), modulation of miRNAs (e.g., miR181b, miR21), multiple protein kinases (e.g., FAK, MAPKs), and heat shock proteins (HLJ1). According to research, curcumin treatment leads to significant elevation in metastatic tumor cross-sectional volume (70%) and zone (46%). Curcumin may enhance LLC's metastatic growth in mice by elevating the concentration of VEGF, angiogenic factors, monocyte chemotactic protein-1 (MCP-1), and IL-1β.

In addition to the possible pharmaceutical effects of curcumin, the safety and relevant therapeutic dose should also be established, given reports on the side effects of curcumin in cancer therapy. Future clinical and preclinical investigations on anti-metastasis properties of curcumin should be designed in a way that indicates the safety and effectiveness of curcumin in inhibiting cancer metastasis.

It has been found that curcumin nanoparticles improve their anticancer properties via cancer cellular uptake enhancement, targeted zone internalization, and high bioavailability. Polymeric nanoparticles, polymeric micelles, and liposomes are the regular nano-carriers exploited for curcumin encapsulation. More efforts are needed to improve curcumin nanoparticles for targeted therapy of cancer cells (e.g., nanoparticle coating with peptides/antibodies that bind to upregulated receptors on the cancer cells’ surface) in the future.

References

• 1

  AbeY.HashimotoS.HorieT. (1999). Curcumin Inhibition of Inflammatory Cytokine Production by Human Peripheral Blood Monocytes and Alveolar Macrophages. Pharmacol. Res.39 (1), 41–47. 10.1006/phrs.1998.0404

  • CrossRef
  • Google Scholar

• 2

  AdachiY.LeeC. T.CoffeeK.YamagataN.OhmJ. E.ParkK. H.et al (2002). Effects of Genetic Blockade of the Insulin-like Growth Factor Receptor in Human colon Cancer Cell Lines. Gastroenterology123 (4), 1191–1204. 10.1053/gast.2002.36023

  • CrossRef
  • Google Scholar

• 3

  AggarwalB. B.SurhY.-J.ShishodiaS. (2007). The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, 595. Springer Science & Business Media.

  • Google Scholar

• 4

  AggarwalS.TakadaY.SinghS.MyersJ. N.AggarwalB. B. (2004). Inhibition of Growth and Survival of Human Head and Neck Squamous Cell Carcinoma Cells by Curcumin via Modulation of Nuclear Factor-?B Signaling. Int. J. Cancer111 (5), 679–692. 10.1002/ijc.20333

  • CrossRef
  • Google Scholar

• 5

  AltenburgJ. D.SiddiquiR. A. (2009). Omega-3 Polyunsaturated Fatty Acids Down-Modulate CXCR4 Expression and Function in MDA-MB-231 Breast Cancer Cells. Mol. Cancer Res.7 (7), 1013–1020. 10.1158/1541-7786.mcr-08-0385

  • CrossRef
  • Google Scholar

• 6

  AnandP.KunnumakkaraA. B.NewmanR. A.AggarwalB. B. (2007). Bioavailability of Curcumin: Problems and Promises. Mol. Pharmaceutics4 (6), 807–818. 10.1021/mp700113r

  • CrossRef
  • Google Scholar

• 7

  AquinoG.PannoneG.SantoroA.LiguoriG.FrancoR.SerpicoR.et al (2012). pEGFR-Tyr 845 Expression as Prognostic Factors in Oral Squamous Cell Carcinoma. Cancer Biol. Ther.13 (11), 967–977. 10.4161/cbt.20991

  • CrossRef
  • Google Scholar

• 8

  AryaG.DasM.SahooS. K. (2018). Evaluation of Curcumin Loaded Chitosan/PEG Blended PLGA Nanoparticles for Effective Treatment of Pancreatic Cancer. Biomed. Pharmacother.102, 555–566. 10.1016/j.biopha.2018.03.101

  • CrossRef
  • Google Scholar

• 9

  AshrafizadehM.ZarrabiA.HashemipourM.VosoughM.NajafiM.ShahinozzamanM.et al (2020). Sensing the Scent of Death: Modulation of microRNAs by Curcumin in Gastrointestinal Cancers. Pharmacol. Res.160, 105199. 10.1016/j.phrs.2020.105199

  • CrossRef
  • Google Scholar

• 10

  AxelradJ. E.LichtigerS.YajnikV. (2016). Inflammatory Bowel Disease and Cancer: The Role of Inflammation, Immunosuppression, and Cancer Treatment. Wjg22 (20), 4794–4801. 10.3748/wjg.v22.i20.4794

  • CrossRef
  • Google Scholar

• 11

  BachmeierB. E.NerlichA. G.LichtinghagenR.SommerhoffC. P. (2001). Matrix Metalloproteinases (MMPs) in Breast Cancer Cell Lines of Different Tumorigenicity. Anticancer Res.21 (6a), 3821–3828.

  • Google Scholar

• 12

  BachmeierB. E.BoukampP.LichtinghagenR.FusenigN. E.FinkE.et al (2000). Matrix Metalloproteinases-2,-3,-7,-9 And-10, but Not MMP-11, Are Differentially Expressed in normal, Benign Tumorigenic and Malignant Human Keratinocyte Cell Lines. Biol. Chem.381 (5-6), 497–507. 10.1515/bc.2000.064

  • CrossRef
  • Google Scholar

• 13

  BachmeierB. E.IancuC. M.KillianP. H.KronskiE.MirisolaV.AngeliniG.et al (2009). Overexpression of the ATP Binding Cassette Gene ABCA1 Determines Resistance to Curcumin in M14 Melanoma Cells. Mol. Cancer8, 129. 10.1186/1476-4598-8-129

  • CrossRef
  • Google Scholar

• 14

  BachmeierB. E.NerlichA. G.BoukampP.LichtinghagenR.TschescheH.FritzH.et al (2000). Human Keratinocyte Cell Lines Differ in the Expression of the Collagenolytic Matrix Metalloproteinases-1,-8, and -13 and of TIMP-1. Biol. Chem.381 (5-6), 509–516. 10.1515/bc.2000.065

  • CrossRef
  • Google Scholar

• 15

  BachmeierB.et al (2007). The Chemopreventive Polyphenol Curcumin Prevents Hematogenous Breast Cancer Metastases in Immunodeficient Mice. Cell Physiol Biochem19 (1-4), 137–152. 10.1159/000099202

  • CrossRef
  • Google Scholar

• 16

  BahramiA.FereidouniM.PirroM.BianconiV.SahebkarA. (2019). Modulation of Regulatory T Cells by Natural Products in Cancer. Cancer Lett.459, 72–85. 10.1016/j.canlet.2019.06.001

  • CrossRef
  • Google Scholar

• 17

  BahramiA.MajeedM.SahebkarA. (2019). Curcumin: a Potent Agent to Reverse Epithelial-To-Mesenchymal Transition. Cell Oncol.42 (4), 405–421. 10.1007/s13402-019-00442-2

  • CrossRef
  • Google Scholar

• 18

  BakhoumS. F.NgoB.LaughneyA. M.CavalloJ.-A.MurphyC. J.LyP.et al (2018). Chromosomal Instability Drives Metastasis through a Cytosolic DNA Response. Nature553 (7689), 467–472. 10.1038/nature25432

  • CrossRef
  • Google Scholar

• 19

  BanerjiA.ChakrabartiJ.MitraA.ChatterjeeA. (2004). Effect of Curcumin on Gelatinase A (MMP-2) Activity in B16F10 Melanoma Cells. Cancer Lett.211 (2), 235–242. 10.1016/j.canlet.2004.02.007

  • CrossRef
  • Google Scholar

• 20

  BaoB.AzmiA. S.AliS.ZaiemF.SarkarF. H.et al (2012). Hypoxia-induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment. PLoS One7 (12), e50165. 10.1371/journal.pone.0050165

  • CrossRef
  • Google Scholar

• 21

  BielenbergD. R.ZetterB. R. (2015). The Contribution of Angiogenesis to the Process of Metastasis. Cancer J.21 (4), 267–273. 10.1097/ppo.0000000000000138

  • CrossRef
  • Google Scholar

• 22

  BishtS.MizumaM.FeldmannG.OttenhofN. A.HongS.-M.PramanikD.et al (2010). Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer. Mol. Cancer Ther.9 (8), 2255–2264. 10.1158/1535-7163.mct-10-0172

  • CrossRef
  • Google Scholar

• 23

  BondM.et al (2001). Inhibition of Transcription Factor NF-Κb Reduces Matrix Metalloproteinase-1, -3 and -9 Production by Vascular Smooth Muscle Cells. Cardiovasc. Res.50 (3), 556–565. 10.1016/s0008-6363(01)00220-6

  • CrossRef
  • Google Scholar

• 24

  BosJ. L. (1989). Ras Oncogenes in Human Cancer: a Review. Cancer Res.49 (17), 4682–4689.

  • Google Scholar

• 25

  BrooksS. A.Lomax-BrowneH. J.CarterT. M.KinchC. E.HallD. M. S. (2010). Molecular Interactions in Cancer Cell Metastasis. Acta Histochem.112 (1), 3–25. 10.1016/j.acthis.2008.11.022

  • CrossRef
  • Google Scholar

• 26

  BuhrmannC.KraeheP.LuedersC.ShayanP.GoelA.ShakibaeiM.et al (2014). Curcumin Suppresses Crosstalk between colon Cancer Stem Cells and Stromal Fibroblasts in the Tumor Microenvironment: Potential Role of EMT. PLoS One9 (9), e107514. 10.1371/journal.pone.0107514

  • CrossRef
  • Google Scholar

• 27

  BuhrmannC.PopperB.KunnumakkaraA. B.AggarwalB. B.ShakibaeiM.et al (2019). Evidence that Calebin A, a Component of Curcuma Longa Suppresses NF-B Mediated Proliferation, Invasion and Metastasis of Human Colorectal Cancer Induced by TNF-β (Lymphotoxin). Nutrients11 (12). 10.3390/nu11122904

  • CrossRef
  • Google Scholar

• 28

  Calibasi-KocalG.PakdemirliA.BayrakS.OzupekN. M.SeverT.BasbinarY.et al (2019). Curcumin Effects on Cell Proliferation, Angiogenesis and Metastasis in Colorectal Cancer. J. Buon24 (4), 1482–1487.

  • Google Scholar

• 29

  CampbellP. M.DerC. J. (2004). Oncogenic Ras and its Role in Tumor Cell Invasion and Metastasis. Semin. Cancer Biol.14 (2), 105–114. 10.1016/j.semcancer.2003.09.015

  • CrossRef
  • Google Scholar

• 30

  CaoL.LiuJ.ZhangL.XiaoX.LiW. (2016). Curcumin Inhibits H2O2-Induced Invasion and Migration of Human Pancreatic Cancer via Suppression of the ERK/NF-κB Pathway. Oncol. Rep.36 (4), 2245–2251. 10.3892/or.2016.5044

  • CrossRef
  • Google Scholar

• 31

  CaoL.XiaoX.LeiJ.DuanW.MaQ.LiW. (2016). Curcumin Inhibits Hypoxia-Induced Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells via Suppression of the Hedgehog Signaling Pathway. Oncol. Rep.35 (6), 3728–3734. 10.3892/or.2016.4709

  • CrossRef
  • Google Scholar

• 32

  ChangJ.ErlerJ. (2014). Hypoxia-mediated Metastasis. Adv. Exp. Med. Biol.772, 55–81. 10.1007/978-1-4614-5915-6_3

  • CrossRef
  • Google Scholar

• 33

  ChenA.XuJ.JohnsonA. C. (2006). Curcumin Inhibits Human colon Cancer Cell Growth by Suppressing Gene Expression of Epidermal Growth Factor Receptor through Reducing the Activity of the Transcription Factor Egr-1. Oncogene25 (2), 278–287. 10.1038/sj.onc.1209019

  • CrossRef
  • Google Scholar

• 34

  ChenC. C.SureshbabulM.ChenH. W.LinY. S.LeeJ. Y.HongQ. S.et al (2013). Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer. Evid. Based Complement. Alternat Med.2013, 541695. 10.1155/2013/541695

  • CrossRef
  • Google Scholar

• 35

  ChenJ. W.TangY. L.LiuH.ZhuZ. Y.LüD.GengN.et al (2011). Anti-proliferative and Anti-metastatic Effects of Curcumin on Oral Cancer Cells. Hua Xi Kou Qiang Yi Xue Za Zhi29 (1), 83–86.

  • Google Scholar

• 36

  ChenQ.-y.ZhengY.JiaoD.-m.ChenF.-y.HuH.-z.WuY.-q.et al (2014). Curcumin Inhibits Lung Cancer Cell Migration and Invasion through Rac1-dependent Signaling Pathway. J. Nutr. Biochem.25 (2), 177–185. 10.1016/j.jnutbio.2013.10.004

  • CrossRef
  • Google Scholar

• 37

  ChenW.ZouP.ZhaoZ.WengQ.ChenX.YingS.et al (2016). Selective Killing of Gastric Cancer Cells by a Small Molecule via Targeting TrxR1 and ROS-Mediated ER Stress Activation. Oncotarget7 (13), 16593–16609. 10.18632/oncotarget.7565

  • CrossRef
  • Google Scholar

• 38

  CheungK. J.EwaldA. J. (2016). A Collective Route to Metastasis: Seeding by Tumor Cell Clusters. Science352 (6282), 167–169. 10.1126/science.aaf6546

  • CrossRef
  • Google Scholar

• 39

  ChinniS. R.YamamotoH.DongZ.SabbotaA.BonfilR. D.CherM. L. (2008). CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone. Mol. Cancer Res.6 (3), 446–457. 10.1158/1541-7786.mcr-07-0117

  • CrossRef
  • Google Scholar

• 40

  ChristoforiG. (2006). New Signals from the Invasive Front. Nature441 (7092), 444–450. 10.1038/nature04872

  • CrossRef
  • Google Scholar

• 41

  ChungH.LeeS.-G.KimH.HongD.ChungJ.StroncekD.et al (2009). Serum High Mobility Group Box-1 (HMGB1) Is Closely Associated with the Clinical and Pathologic Features of Gastric Cancer. J. Translational Med.7, 38. 10.1186/1479-5876-7-38

  • CrossRef
  • Google Scholar

• 42

  ClarkA. G.VignjevicD. M. (2015). Modes of Cancer Cell Invasion and the Role of the Microenvironment. Curr. Opin. Cel Biol.36, 13–22. 10.1016/j.ceb.2015.06.004

  • CrossRef
  • Google Scholar

• 43

  CowinP.RowlandsT. M.HatsellS. J. (2005). Cadherins and Catenins in Breast Cancer. Curr. Opin. Cel Biol.17 (5), 499–508. 10.1016/j.ceb.2005.08.014

  • CrossRef
  • Google Scholar

• 44

  CraeneB. D.BerxG. (2013). Regulatory Networks Defining EMT during Cancer Initiation and Progression. Nat. Rev. Cancer13 (2), 97–110. 10.1038/nrc3447

  • CrossRef
  • Google Scholar

• 45

  DaW.ZhangJ.ZhangR.ZhuJ. (2019). Curcumin Inhibits the Lymphangiogenesis of Gastric Cancer Cells by Inhibiton of HMGB1/VEGF-D Signaling. Int. J. Immunopathol Pharmacol.33, 2058738419861600. 10.1177/2058738419861600

  • CrossRef
  • Google Scholar

• 46

  DaW.ZhuJ.WangL.SunQ. (2015). Curcumin Suppresses Lymphatic Vessel Density in an In Vivo Human Gastric Cancer Model. Tumor Biol.36 (7), 5215–5223. 10.1007/s13277-015-3178-8

  • CrossRef
  • Google Scholar

• 47

  DanielsD. L.WeisW. I. (2005). β-Catenin Directly Displaces Groucho/TLE Repressors from Tcf/Lef in Wnt-Mediated Transcription Activation. Nat. Struct. Mol. Biol.12 (4), 364–371. 10.1038/nsmb912

  • CrossRef
  • Google Scholar

• 48

  DasS. K.MajiS.WechmanS. L.BhoopathiP.PradhanA. K.TalukdarS.et al (2020). MDA-9/Syntenin (SDCBP): Novel Gene and Therapeutic Target for Cancer Metastasis. Pharmacol. Res.155, 104695. 10.1016/j.phrs.2020.104695

  • CrossRef
  • Google Scholar

• 49

  de CamposP. S.MatteB. F.DielL. F.JesusL. H.BernardiL.AlvesA. M.et al (2017). Low Doses ofCurcuma longaModulates Cell Migration and Cell-Cell Adhesion. Phytother. Res.31 (9), 1433–1440. 10.1002/ptr.5872

  • CrossRef
  • Google Scholar

• 50

  DeepakK. G. K.VempatiR.NagarajuG. P.DasariV. R.S.N.RaoD. N.et al (2020). Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer. Pharmacol. Res.153, 104683. 10.1016/j.phrs.2020.104683

  • CrossRef
  • Google Scholar

• 51

  DoumiatiS.HauptK.RossiC. (2012). Autophosphorylation Activation and Inhibition by Curcumin of the Epidermal Growth Factor Receptor Reconstituted in Liposomes. J. Mol. Recognit.25 (11), 623–629. 10.1002/jmr.2194

  • CrossRef
  • Google Scholar

• 52

  DuY.LongQ.ZhangL.ShiY.LiuX.LiX.et al (2015). Curcumin Inhibits Cancer-Associated Fibroblast-Driven Prostate Cancer Invasion through MAOA/mTOR/HIF-1α Signaling. Int. J. Oncol.47 (6), 2064–2072. 10.3892/ijo.2015.3202

  • CrossRef
  • Google Scholar

• 53

  EgebladM.WerbZ. (2002). New Functions for the Matrix Metalloproteinases in Cancer Progression. Nat. Rev. Cancer2 (3), 161–174. 10.1038/nrc745

  • CrossRef
  • Google Scholar

• 54

  EsmatabadiM. J. D.FarhangiB.SafariZ.KazerooniH.ShirzadH.ZolghadrF.et al (2015). Dendrosomal Curcumin Inhibits Metastatic Potential of Human SW480 colon Cancer Cells through Down-Regulation of Claudin1, Zeb1 and Hef1-1 Gene Expression. Asian Pac. J. Cancer Prev.16 (6), 2473–2481. 10.7314/apjcp.2015.16.6.2473

  • CrossRef
  • Google Scholar

• 55

  Faleiro-RodriguesC.Macedo-PintoI.PereiraD.LopesC. S. (2004). Prognostic Value of E-Cadherin Immunoexpression in Patients with Primary Ovarian Carcinomas. Ann. Oncol.15 (10), 1535–1542. 10.1093/annonc/mdh387

  • CrossRef
  • Google Scholar

• 56

  FanC.-C.WangT.-Y.ChengY.-A.JiangS. S.ChengC.-W.LeeA. Y.-L.et al (2013). Expression of E-Cadherin, Twist, and P53 and Their Prognostic Value in Patients with Oral Squamous Cell Carcinoma. J. Cancer Res. Clin. Oncol.139 (10), 1735–1744. 10.1007/s00432-013-1499-9

  • CrossRef
  • Google Scholar

• 57

  FanL.LiA.LiW.CaiP.YangB.ZhangM.et al (2014). Novel Role of Sarco/endoplasmic Reticulum Calcium ATPase 2 in Development of Colorectal Cancer and its Regulation by F36, a Curcumin Analog. Biomed. Pharmacother.68 (8), 1141–1148. 10.1016/j.biopha.2014.10.014

  • CrossRef
  • Google Scholar

• 58

  FanR.LiX.DengJ.GaoX.ZhouL.ZhengY.et al (2016). Dual Drug Loaded Biodegradable Nanofibrous Microsphere for Improving Anti-Colon Cancer Activity. Sci. Rep.6, 28373. 10.1038/srep28373

  • CrossRef
  • Google Scholar

• 59

  Fischer-FodorE.MiklasR.RisianovaL.CenariuM.GrosuI. G.ViragP.et al (2017). Novel Palladium(II) Complexes that Influence Prominin-1/CD133 Expression and Stem Cell Factor Release in Tumor Cells. Molecules22 (4). 10.3390/molecules22040561

  • CrossRef
  • Google Scholar

• 60

  FoddeR.BrabletzT. (2007). Wnt/β-catenin Signaling in Cancer Stemness and Malignant Behavior. Curr. Opin. Cel Biol.19 (2), 150–158. 10.1016/j.ceb.2007.02.007

  • CrossRef
  • Google Scholar

• 61

  FouadY. A.AaneiC. (2017). Revisiting the Hallmarks of Cancer. Am. J. Cancer Res.7 (5), 1016–1036.

  • Google Scholar

• 62

  FouaniL.MenezesS. V.PaulsonM.RichardsonD. R.KovacevicZ. (2017). Metals and Metastasis: Exploiting the Role of Metals in Cancer Metastasis to Develop Novel Anti-metastatic Agents. Pharmacol. Res.115, 275–287. 10.1016/j.phrs.2016.12.001

  • CrossRef
  • Google Scholar

• 63

  FrancíC.TakkunenM.DaveN.AlamedaF.GómezS.RodríguezR.et al (2006). Expression of Snail Protein in Tumor-Stroma Interface. Oncogene25 (37), 5134–5144. 10.1038/sj.onc.1209519

  • CrossRef
  • Google Scholar

• 64

  FrancoR.PirozziG.ScalaS.CantileM.ScognamiglioG.CamerlingoR.et al (2012). CXCL12-binding Receptors Expression in Non-small Cell Lung Cancer Relates to Tumoral Microvascular Density and CXCR4 Positive Circulating Tumoral Cells in Lung Draining Venous Blood. Eur. J. Cardio-Thoracic Surg.41 (2), 368–375. 10.1016/j.ejcts.2011.05.009

  • CrossRef
  • Google Scholar

• 65

  FriedlP. (2004). Prespecification and Plasticity: Shifting Mechanisms of Cell Migration. Curr. Opin. Cel Biol.16 (1), 14–23. 10.1016/j.ceb.2003.11.001

  • CrossRef
  • Google Scholar

• 66

  GreilR.Greil-ResslerS.WeissL.SchönliebC.MagnesT.RadlB.et al (2018). A Phase 1 Dose-Escalation Study on the Safety, Tolerability and Activity of Liposomal Curcumin (Lipocurc) in Patients with Locally Advanced or Metastatic Cancer. Cancer Chemother. Pharmacol.82 (4), 695–706. 10.1007/s00280-018-3654-0

  • CrossRef
  • Google Scholar

• 67

  GuX.ZhangQ.ZhangW.ZhuL. (2019). Curcumin Inhibits Liver Metastasis of Gastric Cancer through Reducing Circulating Tumor Cells. Aging11 (5), 1501–1509. 10.18632/aging.101848

  • CrossRef
  • Google Scholar

• 68

  GuerreroS.Inostroza-RiquelmeM.Contreras-OrellanaP.Diaz-GarciaV.LaraP.Vivanco-PalmaA.et al (2018). Curcumin-loaded Nanoemulsion: a New Safe and Effective Formulation to Prevent Tumor Reincidence and Metastasis. Nanoscale10 (47), 22612–22622. 10.1039/c8nr06173d

  • CrossRef
  • Google Scholar

• 69

  GundemG.aufnm.Van LooP.KremeyerB.AlexandrovL. B.TubioJ. M. C.et al (2015). The Evolutionary History of Lethal Metastatic Prostate Cancer. Nature520 (7547), 353–357. 10.1038/nature14347

  • CrossRef
  • Google Scholar

• 70

  HanH.WeiW.ChuW.LiuK.TianY.JiangZ.et al (2017). Muscle Conditional Medium Reduces Intramuscular Adipocyte Differentiation and Lipid Accumulation through Regulating Insulin Signaling. Int. J. Mol. Sci.18 (8). 10.3390/ijms18081799

  • CrossRef
  • Google Scholar

• 71

  HanY. P.TuanT. L.WuH.HughesM.GarnerW. L., (2001). TNF-alpha Stimulates Activation of Pro-MMP2 in Human Skin through NF-(kappa)B Mediated Induction of MT1-MMP. J. Cel Sci114 (Pt 1), 131–139. 10.1242/jcs.114.1.131

  • CrossRef
  • Google Scholar

• 72

  HanahanD.WeinbergR. A. (2011). Hallmarks of Cancer: the Next Generation. Cell144 (5), 646–674. 10.1016/j.cell.2011.02.013

  • CrossRef
  • Google Scholar

• 73

  HatakeyamaK.YamakawaY.FukudaY.OhshimaK.Wakabayashi-NakaoK.SakuraN.et al (2015). A Novel Splice Variant of XIAP-Associated Factor 1 (XAF1) Is Expressed in Peripheral Blood Containing Gastric Cancer-Derived Circulating Tumor Cells. Gastric Cancer18 (4), 751–761. 10.1007/s10120-014-0426-3

  • CrossRef
  • Google Scholar

• 74

  HelsonL.BolgerG.MajeedM.VcelarB.PucajK.MatabudulD. (2012). Infusion Pharmacokinetics of Lipocurc™ (Liposomal Curcumin) and its Metabolite Tetrahydrocurcumin in Beagle Dogs. Anticancer Res.32 (10), 4365–4370.

  • Google Scholar

• 75

  HongJ. H.AhnK. S.BaeE.JeonS. S.ChoiH. Y. (2006). The Effects of Curcumin on the Invasiveness of Prostate Cancer In Vitro and In Vivo. Prostate Cancer Prostatic Dis.9 (2), 147–152. 10.1038/sj.pcan.4500856

  • CrossRef
  • Google Scholar

• 76

  HosseiniS. A.ZandH.CheraghpourM. (2019). The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A Possible Mechanism Underlying the Anti-growth and Anti-migration in Chemoresistant Colorectal Cancer Cells. Medicina (Kaunas)55 (4). 10.3390/medicina55040090

  • CrossRef
  • Google Scholar

• 77

  HuangM. T.LouY. R.MaW.NewmarkH. L.ReuhlK. R.ConneyA. H. (1994). Inhibitory Effects of Dietary Curcumin on Forestomach, Duodenal, and colon Carcinogenesis in Mice. Cancer Res.54 (22), 5841–5847.

  • Google Scholar

• 78

  HuangX.GanG.WangX.XuT.XieW. (2019). The HGF-MET axis Coordinates Liver Cancer Metabolism and Autophagy for Chemotherapeutic Resistance. Autophagy15 (7), 1258–1279. 10.1080/15548627.2019.1580105

  • CrossRef
  • Google Scholar

• 79

  HuberG. F.ZülligL.SoltermannA.RoessleM.GrafN.HaerleS. K.et al (2011). Down Regulation of E-Cadherin (ECAD) - a Predictor for Occult Metastatic Disease in sentinel Node Biopsy of Early Squamous Cell Carcinomas of the Oral Cavity and Oropharynx. BMC Cancer11 (217), 1–8. 10.1186/1471-2407-11-217

  • CrossRef
  • Google Scholar

• 80

  InanoH.OnodaM.InafukuN.KubotaM.KamadaY.OsawaT.et al (1999). Chemoprevention by Curcumin during the Promotion Stage of Tumorigenesis of Mammary Gland in Rats Irradiated with Gamma-Rays. Carcinogenesis20 (6), 1011–1018. 10.1093/carcin/20.6.1011

  • CrossRef
  • Google Scholar

• 81

  IsmailN. I.OthmanI. (2019). Mechanism of Apoptosis Induced by Curcumin in Colorectal Cancer.Int. J. Mol. Sci.20(10).10.3390/ijms20102454

  • CrossRef
  • Google Scholar

• 82

  IzzoJ. G.CorreaA. M.WuT.-T.MalhotraU.ChaoC. K. S.LuthraR.et al (2006). Pretherapy Nuclear Factor-Κb Status, Chemoradiation Resistance, and Metastatic Progression in Esophageal Carcinoma. Mol. Cancer Ther.5 (11), 2844–2850. 10.1158/1535-7163.mct-06-0351

  • CrossRef
  • Google Scholar

• 83

  JiaoD.JianW.LuW.TangChenX. J.MouH.et al (2016). Curcumin Inhibited HGF-Induced EMT and Angiogenesis through Regulating C-Met Dependent PI3K/Akt/mTOR Signaling Pathways in Lung Cancer. Mol. Ther. Oncolytics3, 16018. 10.1038/mto.2016.18

  • CrossRef
  • Google Scholar

• 84

  KaifiJ. T.YekebasE. F.SchurrP.ObonyoD.WachowiakR.BuschP.et al (2005). Tumor-cell Homing to Lymph Nodes and Bone Marrow and CXCR4 Expression in Esophageal Cancer. J. Natl. Cancer Inst.97 (24), 1840–1847. 10.1093/jnci/dji431

  • CrossRef
  • Google Scholar

• 85

  KalluriR.ZeisbergM. (2006). Fibroblasts in Cancer. Nat. Rev. Cancer6 (5), 392–401. 10.1038/nrc1877

  • CrossRef
  • Google Scholar

• 86

  KasashimaH.YashiroM.KinoshitaH.FukuokaT.MorisakiT.MasudaG.et al (2014). Lysyl Oxidase-like 2 (LOXL2) from Stromal Fibroblasts Stimulates the Progression of Gastric Cancer. Cancer Lett.354 (2), 438–446. 10.1016/j.canlet.2014.08.014

  • CrossRef
  • Google Scholar

• 87

  KatsunoY.LamouilleS.DerynckR. (2013). TGF-β Signaling and Epithelial-Mesenchymal Transition in Cancer Progression. Curr. Opin. Oncol.25 (1), 76–84. 10.1097/cco.0b013e32835b6371

  • CrossRef
  • Google Scholar

• 88

  KimD.-C.LeeW.BaeJ.-S. (2011). Vascular Anti-inflammatory Effects of Curcumin on HMGB1-Mediated Responses In Vitro. Inflamm. Res.60 (12), 1161–1168. 10.1007/s00011-011-0381-y

  • CrossRef
  • Google Scholar

• 89

  KimH. J.ParkS. Y.ParkO. J.KimY.-M. (2013). Curcumin Suppresses Migration and Proliferation of Hep3B Hepatocarcinoma Cells through Inhibition of the Wnt Signaling Pathway. Mol. Med. Rep.8 (1), 282–286. 10.3892/mmr.2013.1497

  • CrossRef
  • Google Scholar

• 90

  KimJ.-M.NohE.-M.KwonK.-B.KimJ.-S.YouY.-O.HwangJ.-K.et al (2012). Curcumin Suppresses the TPA-Induced Invasion through Inhibition of PKCα-dependent MMP-Expression in MCF-7 Human Breast Cancer Cells. Phytomedicine19 (12), 1085–1092. 10.1016/j.phymed.2012.07.002

  • CrossRef
  • Google Scholar

• 91

  KimJ. H.GuptaS. C.ParkB.YadavV. R.AggarwalB. B. (2012). Turmeric (Curcuma Longa ) Inhibits Inflammatory Nuclear Factor (NF)-κB and NF-Κb-Regulated Gene Products and Induces Death Receptors Leading to Suppressed Proliferation, Induced Chemosensitization, and Suppressed Osteoclastogenesis. Mol. Nutr. Food Res.56 (3), 454–465. 10.1002/mnfr.201100270

  • CrossRef
  • Google Scholar

• 92

  KnottS. R. V.WagenblastE.KhanS.KimS. Y.SotoM.WagnerM.et al (2018). Asparagine Bioavailability Governs Metastasis in a Model of Breast Cancer. Nature554 (7692), 378–381. 10.1038/nature25465

  • CrossRef
  • Google Scholar

• 93

  KunnumakkaraA. B.DiagaradjaneP.AnandP.KuzhuvelilH. B.DeorukhkarA.GelovaniJ.et al (2009). Curcumin Sensitizes Human Colorectal Cancer to Capecitabine by Modulation of Cyclin D1, COX‐2, MMP‐9, VEGF and CXCR4 Expression in an Orthotopic Mouse Model. Int. J. Cancer125 (9), 2187–2197. 10.1002/ijc.24593

  • CrossRef
  • Google Scholar

• 94

  LambertA. W.PattabiramanD. R.WeinbergR. A. (2017). Emerging Biological Principles of Metastasis. Cell168 (4), 670–691. 10.1016/j.cell.2016.11.037

  • CrossRef
  • Google Scholar

• 95

  LarssonS. C.OrsiniN.WolkA. (2005). Diabetes Mellitus and Risk of Colorectal Cancer: a Meta-Analysis. J. Natl. Cancer Inst.97 (22), 1679–1687. 10.1093/jnci/dji375

  • CrossRef
  • Google Scholar

• 96

  LeeA. Y.-L.FanC.-C.ChenY.-A.ChengC.-W.SungY.-J.HsuC.-P.et al (2015). Curcumin Inhibits Invasiveness and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma through Reducing Matrix Metalloproteinase 2, 9 and Modulating P53-E-Cadherin Pathway. Integr. Cancer Ther.14 (5), 484–490. 10.1177/1534735415588930

  • CrossRef
  • Google Scholar

• 97

  LeeB. C.LeeT. H.AvrahamS.AvrahamH. K. (2004). Involvement of the Chemokine Receptor CXCR4 and its Ligand Stromal Cell-Derived Factor 1alpha in Breast Cancer Cell Migration through Human Brain Microvascular Endothelial Cells. Mol. Cancer Res.2 (6), 327–338.

  • Google Scholar

• 98

  LeeD. J.KangS. W. (2013). RETRACTED ARTICLE: Reactive Oxygen Species and Tumor Metastasis. Mol. Cell35 (2), 93–98. 10.1007/s10059-013-0034-9

  • CrossRef
  • Google Scholar

• 99

  LeeJ.-G.McKinneyK. Q.PavlopoulosA. J.ParkJ.-H.HwangS. (2014). Data Supporting the Identification of Anti-metastatic Drug and Natural Compound Targets in Isogenic Colorectal Cancer Cells. Data in Brief1, 73–75. 10.1016/j.dib.2014.10.005

  • CrossRef
  • Google Scholar

• 100

  LeeJ.-G.McKinneyK. Q.PavlopoulosA. J.ParkJ.-H.HwangS. (2015). Identification of Anti-metastatic Drug and Natural Compound Targets in Isogenic Colorectal Cancer Cells. J. Proteomics113, 326–336. 10.1016/j.jprot.2014.10.009

  • CrossRef
  • Google Scholar

• 101

  LeeS. S.et al (2013). Elevated Snail Expression Mediates Tumor Progression in Areca Quid Chewing-Associated Oral Squamous Cell Carcinoma via Reactive Oxygen Species. PLoS One8 (7), e67985. 10.1371/journal.pone.0067985

  • CrossRef
  • Google Scholar

• 102

  LeiJ.MaJ.MaQ.LiX.LiuH.XuQ.et al (2013). Hedgehog Signaling Regulates Hypoxia Induced Epithelial to Mesenchymal Transition and Invasion in Pancreatic Cancer Cells via a Ligand-independent Manner. Mol. Cancer12, 66. 10.1186/1476-4598-12-66

  • CrossRef
  • Google Scholar

• 103

  LiL.AhmedB.MehtaK.KurzrockR. (2007). Liposomal Curcumin with and without Oxaliplatin: Effects on Cell Growth, Apoptosis, and Angiogenesis in Colorectal Cancer. Mol. Cancer Ther.6 (4), 1276–1282. 10.1158/1535-7163.mct-06-0556

  • CrossRef
  • Google Scholar

• 104

  LiL.BraitehF. S.KurzrockR. (2005). Liposome-encapsulated Curcumin. Cancer104 (6), 1322–1331. 10.1002/cncr.21300

  • CrossRef
  • Google Scholar

• 105

  LiM.YueG. G.-L.TsuiS. K.-W.FungK.-P.LauC. B.-S. (2018). Turmeric Extract, with Absorbable Curcumin, Has Potent Anti-metastatic Effect In Vitro and In Vivo. Phytomedicine46, 131–141. 10.1016/j.phymed.2018.03.065

  • CrossRef
  • Google Scholar

• 106

  LiW.JiangZ.XiaoX.WangZ.WuZ.MaQ.et al (2018). Curcumin Inhibits Superoxide Dismutase-Induced Epithelial-To-Mesenchymal Transition via the PI3K/Akt/NF-Κb Pathway in Pancreatic Cancer Cells. Int. J. Oncol.52 (5), 1593–1602. 10.3892/ijo.2018.4295

  • CrossRef
  • Google Scholar

• 107

  LiW.MaZ.MaJ.LiX.XuQ.DuanW.et al (2015). Hydrogen Peroxide Mediates Hyperglycemia-Induced Invasive Activity via ERK and P38 MAPK in Human Pancreatic Cancer. Oncotarget6 (31), 31119–31133. 10.18632/oncotarget.5045

  • CrossRef
  • Google Scholar

• 108

  LiangZ.LuL.MaoJ.LiX.QianH.XuW.et al (2017). Curcumin Reversed Chronic Tobacco Smoke Exposure Induced Urocystic EMT and Acquisition of Cancer Stem Cells Properties via Wnt/β-Catenin. Cell Death Dis8 (10), e3066. 10.1038/cddis.2017.452

  • CrossRef
  • Google Scholar

• 109

  LimaF. T.EloyJ. O.RuizA.PetrilliR.RaspantiniG.NogueiraK. A. B.et al (2018). The Curcumin Analog CH-5 Exerts Anticancer Effects in Human Osteosarcoma Cells via Modulation of Transcription Factors p53/Sp1. Int. J. Mol. Sci.19 (7). 10.3390/ijms19071909

  • CrossRef
  • Google Scholar

• 110

  LinL.-I.KeY.-F.KoY.-C.LinJ.-K. (1998). Curcumin Inhibits SK-Hep-1 Hepatocellular Carcinoma Cell Invasion In Vitro and Suppresses Matrix Metalloproteinase-9 Secretion. Oncology55 (4), 349–353. 10.1159/000011876

  • CrossRef
  • Google Scholar

• 111

  LinL.FuchsJ.LiC.OlsonV.Bekaii-SaabT.LinJ.et al (2011). STAT3 Signaling Pathway Is Necessary for Cell Survival and Tumorsphere Forming Capacity in ALDH⁺/CD133⁺ Stem Cell-like Human colon Cancer Cells. Biochem. Biophys. Res. Commun.416 (3-4), 246–251. 10.1016/j.bbrc.2011.10.112

  • CrossRef
  • Google Scholar

• 112

  LinM.-C.HuangM.-J.LiuC.-H.YangT.-L.HuangM.-C. (2014). GALNT2 Enhances Migration and Invasion of Oral Squamous Cell Carcinoma by Regulating EGFR Glycosylation and Activity. Oral Oncol.50 (5), 478–484. 10.1016/j.oraloncology.2014.02.003

  • CrossRef
  • Google Scholar

• 113

  LinM.-L.LuY.-C.ChenH.-Y.LeeC.-C.ChungJ.-G.ChenS.-S. (2014). Suppressing the Formation of Lipid Raft-Associated Rac1/PI3K/Akt Signaling Complexes by Curcumin Inhibits SDF-1α-Induced Invasion of Human Esophageal Carcinoma Cells. Mol. Carcinog.53 (5), 360–379. 10.1002/mc.21984

  • CrossRef
  • Google Scholar

• 114

  LinS.-S.LaiK.-C.HsuS.-C.YangJ.-S.KuoC.-L.LinJ.-P.et al (2009). Curcumin Inhibits the Migration and Invasion of Human A549 Lung Cancer Cells through the Inhibition of Matrix Metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett.285 (2), 127–133. 10.1016/j.canlet.2009.04.037

  • CrossRef
  • Google Scholar

• 115

  LintzM.MuñozA.Reinhart-KingC. A. (2017). The Mechanics of Single Cell and Collective Migration of Tumor Cells. J. biomechanical Eng.139 (2), 0210051–0210059. 10.1115/1.4035121

  • CrossRef
  • Google Scholar

• 116

  LiuD.LiuJ.WangC.LinB.LiuQ.HaoY.et al (2011). The Stimulation of IGF-1R Expression by Lewis(y) Antigen Provides a Powerful Development Mechanism of Epithelial Ovarian Carcinoma. Ijms12 (10), 6781–6795. 10.3390/ijms12106781

  • CrossRef
  • Google Scholar

• 117

  LiuW. L.ChangJ. M.ChongI. W.HungY. L.ChenY. H.HuangW. T.et al (2017). Curcumin Inhibits LIN-28A through the Activation of miRNA-98 in the Lung Cancer Cell Line A549. Molecules22 (6). 10.3390/molecules22060929

  • CrossRef
  • Google Scholar

• 118

  LunardiS.MuschelR. J.BrunnerT. B. (2014). The Stromal Compartments in Pancreatic Cancer: Are There Any Therapeutic Targets?Cancer Lett.343 (2), 147–155. 10.1016/j.canlet.2013.09.039

  • CrossRef
  • Google Scholar

• 119

  LuoX.LiuJ.WangH.LuH. (2020). Metabolomics Identified New Biomarkers for the Precise Diagnosis of Pancreatic Cancer and Associated Tissue Metastasis. Pharmacol. Res.156, 104805. 10.1016/j.phrs.2020.104805

  • CrossRef
  • Google Scholar

• 120

  LuzziK. J.MacDonaldI. C.SchmidtE. E.KerkvlietN.MorrisV. L.ChambersA. F.et al (1998). Multistep Nature of Metastatic Inefficiency. Am. J. Pathol.153 (3), 865–873. 10.1016/s0002-9440(10)65628-3

  • CrossRef
  • Google Scholar

• 121

  LvX.-P. (2017). Gastrointestinal Tract Cancers: Genetics, Heritability and Germ Line Mutations. Oncol. Lett.13 (3), 1499–1508. 10.3892/ol.2017.5629

  • CrossRef
  • Google Scholar

• 122

  MachC. M.MathewL.MosleyS. A.KurzrockR.SmithJ. A. (2009). Determination of Minimum Effective Dose and Optimal Dosing Schedule for Liposomal Curcumin in a Xenograft Human Pancreatic Cancer Model. Anticancer Res.29 (6), 1895–1899.

  • Google Scholar

• 123

  MadamsettyV. S.PalK.KeshavanS.CaulfieldT. R.DuttaS. K.WangE.et al (2019). Development of Multi-Drug Loaded PEGylated Nanodiamonds to Inhibit Tumor Growth and Metastasis in Genetically Engineered Mouse Models of Pancreatic Cancer. Nanoscale11 (45), 22006–22018. 10.1039/c9nr05478b

  • CrossRef
  • Google Scholar

• 124

  MaitraA. (2019). Molecular Envoys Pave the Way for Pancreatic Cancer to Invade the Liver. Nature567 (7747), 181–182. 10.1038/d41586-019-00710-z

  • CrossRef
  • Google Scholar

• 125

  MardaniR.HamblinM. R.TaghizadehM.BanafsheH. R.NejatiM.MokhtariM.et al (2020). Nanomicellar-curcumin Exerts its Therapeutic Effects via Affecting Angiogenesis, Apoptosis, and T Cells in a Mouse Model of Melanoma Lung Metastasis. Pathol. - Res. Pract.216 (9), 153082. 10.1016/j.prp.2020.153082

  • CrossRef
  • Google Scholar

• 126

  MartinT. A.GoyalA.WatkinsG.JiangW. G. (2005). Expression of the Transcription Factors Snail, Slug, and Twist and Their Clinical Significance in Human Breast Cancer. Ann. Surg. Oncol.12 (6), 488–496. 10.1245/aso.2005.04.010

  • CrossRef
  • Google Scholar

• 127

  MasekiS.IjichiK.NakanishiH.HasegawaY.OgawaT.MurakamiS. (2013). Efficacy of Gemcitabine and Cetuximab Combination Treatment in Head and Neck Squamous Cell Carcinoma. Mol. Clin. Oncol.1 (5), 918–924. 10.3892/mco.2013.159

  • CrossRef
  • Google Scholar

• 128

  MassaguéJ.ObenaufA. C. (2016). Metastatic Colonization by Circulating Tumour Cells. Nature529 (7586), 298–306. 10.1038/nature17038

  • CrossRef
  • Google Scholar

• 129

  MasudaT.MaekawaT.HidakaK.BandoH.TakedaY.YamaguchiH. (2001). Chemical Studies on Antioxidant Mechanism of Curcumin: Analysis of Oxidative Coupling Products from Curcumin and Linoleate. J. Agric. Food Chem.49 (5), 2539–2547. 10.1021/jf001442x

  • CrossRef
  • Google Scholar

• 130

  MatabudulD.PucajK.BolgerG.VcelarB.MajeedM.HelsonL. (2012). Tissue Distribution of (Lipocurc™) Liposomal Curcumin and Tetrahydrocurcumin Following Two- and Eight-Hour Infusions in Beagle Dogs. Anticancer Res.32 (10), 4359–4364.

  • Google Scholar

• 131

  MegoM.RejlekovaK.ReckovaM.Sycova-MilaZ.ObertovaJ.RajecJ.et al (2016). CXCR4-SDF-1 Interaction Potentially Mediates Trafficking of Circulating Tumor Cells in Primary Breast Cancer. BMC Cancer16, 127. 10.1186/s12885-016-2143-2

  • CrossRef
  • Google Scholar

• 132

  MitraA.ChakrabartiJ.BanerjiA.ChatterjeeA.DasB. R. (2006). Curcumin, a Potential Inhibitor of MMP-2 in Human Laryngeal Squamous Carcinoma Cells HEp2. J. Environ. Pathol. Toxicol. Oncol.25 (4), 679–690. 10.1615/jenvironpatholtoxicoloncol.v25.i4.70

  • CrossRef
  • Google Scholar

• 133

  MohanR.SivakJ.AshtonP.RussoL. A.PhamB. Q.KasaharaN.et al (2000). Curcuminoids Inhibit the Angiogenic Response Stimulated by Fibroblast Growth Factor-2, Including Expression of Matrix Metalloproteinase Gelatinase B. J. Biol. Chem.275 (14), 10405–10412. 10.1074/jbc.275.14.10405

  • CrossRef
  • Google Scholar

• 134

  MudduluruG.George-WilliamJ. N.MuppalaS.AsanganiI. A.KumarswamyR.NelsonL. D.et al (2011). Curcumin Regulates miR-21 Expression and Inhibits Invasion and Metastasis in Colorectal Cancer. Biosci. Rep.31 (3), 185–197. 10.1042/bsr20100065

  • CrossRef
  • Google Scholar

• 135

  MukherjeeS.HussainiR.WhiteR.AtwiD.FriedA.SampatS.et al (2018). TriCurin, a Synergistic Formulation of Curcumin, Resveratrol, and Epicatechin Gallate, Repolarizes Tumor-Associated Macrophages and Triggers an Immune Response to Cause Suppression of HPV+ Tumors. Cancer Immunol. Immunotherimmunotherapy67 (5), 761–774. 10.1007/s00262-018-2130-3

  • CrossRef
  • Google Scholar

• 136

  MüllerA.HomeyB.SotoH.GeN.CatronD.BuchananM. E.et al (2001). Involvement of Chemokine Receptors in Breast Cancer Metastasis. Nature410 (6824), 50–56. 10.1038/35065016

  • CrossRef
  • Google Scholar

• 137

  MuñozP.IliouM. S.EstellerM. (2012). Epigenetic Alterations Involved in Cancer Stem Cell Reprogramming. Mol. Oncol.6 (6), 620–636. 10.1016/j.molonc.2012.10.006

  • CrossRef
  • Google Scholar

• 138

  MurphyG.NagaseH. (2008). Progress in Matrix Metalloproteinase Research. Mol. Aspects Med.29 (5), 290–308. 10.1016/j.mam.2008.05.002

  • CrossRef
  • Google Scholar

• 139

  NagarajuG. P.ZhuS.KoJ. E.AshrithaN.KandimallaR.SnyderJ. P.et al (2015). Antiangiogenic Effects of a Novel Synthetic Curcumin Analogue in Pancreatic Cancer. Cancer Lett.357 (2), 557–565. 10.1016/j.canlet.2014.12.007

  • CrossRef
  • Google Scholar

• 140

  NechushtanH.VainerG.StainbergH.SalmonA. Y.HamburgerT.PeretzT. (2014). A Phase 1/2 of a Combination of Cetuximab and Taxane for "triple Negative" Breast Cancer Patients. The Breast23 (4), 435–438. 10.1016/j.breast.2014.03.003

  • CrossRef
  • Google Scholar

• 141

  NegiP. S.JayaprakashaG. K.Jagan Mohan RaoL.SakariahK. K. (1999). Antibacterial Activity of Turmeric Oil: a Byproduct from Curcumin Manufacture. J. Agric. Food Chem.47 (10), 4297–4300. 10.1021/jf990308d

  • CrossRef
  • Google Scholar

• 142

  NietoM. A.HuangR. Y.-J.JacksonR. A.ThieryJ. P. (2016). EMT: 2016. Cell166 (1), 21–45. 10.1016/j.cell.2016.06.028

  • CrossRef
  • Google Scholar

• 143

  NishikawaM.HashidaM.TakakuraY. (2009). Catalase Delivery for Inhibiting ROS-Mediated Tissue Injury and Tumor Metastasis. Adv. Drug Deliv. Rev.61 (4), 319–326. 10.1016/j.addr.2009.01.001

  • CrossRef
  • Google Scholar

• 144

  OhnishiY.SakamotoT.ZhengguangL.YasuiH.HamadaH.KuboH.et al (2020). Curcumin Inhibits Epithelial-Mesenchymal Transition in Oral Cancer Cells via C-Met Blockade. Oncol. Lett.19 (6), 4177–4182. 10.3892/ol.2020.11523

  • CrossRef
  • Google Scholar

• 145

  OrrùS.NigroE. (2017). A Functional Interplay between IGF-1 and Adiponectin. Int. J. Mol. Sci.18 (10), 2145. 10.3390/ijms18102145

  • CrossRef
  • Google Scholar

• 146

  PanP.HuangY.-W.OshimaK.YearsleyM.ZhangJ.ArnoldM.et al (2019). The Immunomodulatory Potential of Natural Compounds in Tumor-Bearing Mice and Humans. Crit. Rev. Food Sci. Nutr.59 (6), 992–1007. 10.1080/10408398.2018.1537237

  • CrossRef
  • Google Scholar

• 147

  PandaA.GrammatikakisI.YoonJ.-H.AbdelmohsenK. (2013). Posttranscriptional Regulation of Insulin Family Ligands and Receptors. Ijms14 (9), 19202–19229. 10.3390/ijms140919202

  • CrossRef
  • Google Scholar

• 148

  ParasramkaM. A.GuptaS. V. (2012). Synergistic Effect of Garcinol and Curcumin on Antiproliferative and Apoptotic Activity in Pancreatic Cancer Cells. J. Oncol.2012, 709739. 10.1155/2012/709739

  • CrossRef
  • Google Scholar

• 149

  PastushenkoI.BrisebarreA.SifrimA.FioramontiM.RevencoT.BoumahdiS.et al (2018). Identification of the Tumour Transition States Occurring during EMT. Nature556 (7702), 463–468. 10.1038/s41586-018-0040-3

  • CrossRef
  • Google Scholar

• 150

  PhilipS.BulbuleA.KunduG. C. (2004). Matrix Metalloproteinase-2: Mechanism and Regulation of NF-kappaB-Mediated Activation and its Role in Cell Motility and ECM-Invasion. Glycoconj J.21 (8-9), 429–441. 10.1007/s10719-004-5533-7

  • CrossRef
  • Google Scholar

• 151

  PhilipS.BulbuleA.KunduG. C. (2001). Osteopontin Stimulates Tumor Growth and Activation of Promatrix Metalloproteinase-2 through Nuclear Factor-Κb-Mediated Induction of Membrane Type 1 Matrix Metalloproteinase in Murine Melanoma Cells. J. Biol. Chem.276 (48), 44926–44935. 10.1074/jbc.m103334200

  • CrossRef
  • Google Scholar

• 152

  PhilipS.KunduG. C. (2003). Osteopontin Induces Nuclear Factor κB-mediated Promatrix Metalloproteinase-2 Activation through IκBα/IKK Signaling Pathways, and Curcumin (Diferulolylmethane) Down-Regulates These Pathways. J. Biol. Chem.278 (16), 14487–14497. 10.1074/jbc.m207309200

  • CrossRef
  • Google Scholar

• 153

  PikeL. J. (2005). Growth Factor Receptors, Lipid Rafts and Caveolae: an Evolving story. Biochim. Biophys. Acta (Bba) - Mol. Cel Res.1746 (3), 260–273. 10.1016/j.bbamcr.2005.05.005

  • CrossRef
  • Google Scholar

• 154

  RabinowitsG.HaddadR. I. (2012). Overcoming Resistance to EGFR Inhibitor in Head and Neck Cancer: a Review of the Literature. Oral Oncol.48 (11), 1085–1089. 10.1016/j.oraloncology.2012.06.016

  • CrossRef
  • Google Scholar

• 155

  RanjanA. P.MukerjeeA.HelsonL.GuptaR.VishwanathaJ. K. (2013). Efficacy of Liposomal Curcumin in a Human Pancreatic Tumor Xenograft Model: Inhibition of Tumor Growth and Angiogenesis. Anticancer Res.33 (9), 3603–3609.

  • Google Scholar

• 156

  RashmiR.KumarS.KarunagaranD. (2004). Ectopic Expression of Hsp70 Confers Resistance and Silencing its Expression Sensitizes Human colon Cancer Cells to Curcumin-Induced Apoptosis. Carcinogenesis25 (2), 179–187. 10.1093/carcin/bgh213

  • CrossRef
  • Google Scholar

• 157

  RathS.DasL.KokateS. B.GhoshN.DixitP.RoutN.et al (2017). Inhibition of Histone/lysine Acetyltransferase Activity Kills CoCl2-Treated and Hypoxia-Exposed Gastric Cancer Cells and Reduces Their Invasiveness. Int. J. Biochem. Cel Biol.82, 28–40. 10.1016/j.biocel.2016.11.014

  • CrossRef
  • Google Scholar

• 158

  ReckampK. L.FiglinR. A.BurdickM. D.DubinettS. M.ElashoffR. M.StrieterR. M.et al (2009). CXCR4 Expression on Circulating Pan-Cytokeratin Positive Cells Is Associated with Survival in Patients with Advanced Non-small Cell Lung Cancer. BMC Cancer9, 213. 10.1186/1471-2407-9-213

  • CrossRef
  • Google Scholar

• 159

  RichmondP. J.KarayiannakisA. J.NagafuchiA.KaisaryA. V.PignatelliM. (1997). Aberrant E-Cadherin and Alpha-Catenin Expression in Prostate Cancer: Correlation with Patient Survival. Cancer Res.57 (15), 3189–3193.

  • Google Scholar

• 160

  RobertsP. J.DerC. J. (2007). Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase cascade for the Treatment of Cancer. Oncogene26 (22), 3291–3310. 10.1038/sj.onc.1210422

  • CrossRef
  • Google Scholar

• 161

  RosivatzE.BeckerI.SpechtK.FrickeE.LuberB.BuschR.et al (2002). Differential Expression of the Epithelial-Mesenchymal Transition Regulators Snail, SIP1, and Twist in Gastric Cancer. Am. J. Pathol.161 (5), 1881–1891. 10.1016/s0002-9440(10)64464-1

  • CrossRef
  • Google Scholar

• 162

  RoyS. (2013). Difluorinated-curcumin (CDF) Restores PTEN Expression in colon Cancer Cells by Down-Regulating miR-21. PLoS One8 (7), e68543. 10.1371/journal.pone.0068543

  • CrossRef
  • Google Scholar

• 163

  RoyS.LeviE.MajumdarA. P.SarkarF. H. (2012). Expression of miR-34 Is Lost in colon Cancer Which Can Be Re-expressed by a Novel Agent CDF. J. Hematol. Oncol.5, 58. 10.1186/1756-8722-5-58

  • CrossRef
  • Google Scholar

• 164

  SaitoH.TakayaS.OsakiT.IkeguchiM. (2013). Increased Apoptosis and Elevated Fas Expression in Circulating Natural Killer Cells in Gastric Cancer Patients. Gastric Cancer16 (4), 473–479. 10.1007/s10120-012-0210-1

  • CrossRef
  • Google Scholar

• 165

  SankpalU. T.NagarajuG. P.GottipoluS. R.HurtadoM.JordanC. G.SimeckaJ. W.et al (2016). Combination of Tolfenamic Acid and Curcumin Induces colon Cancer Cell Growth Inhibition through Modulating Specific Transcription Factors and Reactive Oxygen Species. Oncotarget7 (3), 3186–3200. 10.18632/oncotarget.6553

  • CrossRef
  • Google Scholar

• 166

  SarfsteinR.BelfioreA.WernerH. (2010). Identification of Insulin-like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells. Cancers2 (2), 233–261. 10.3390/cancers2020233

  • CrossRef
  • Google Scholar

• 167

  SatoskarR. R.ShahS. J.ShenoyS. G. (1986). Evaluation of Anti-inflammatory Property of Curcumin (Diferuloyl Methane) in Patients with Postoperative Inflammation. Int. J. Clin. Pharmacol. Ther. Toxicol.24 (12), 651–654.

  • Google Scholar

• 168

  SgambatoA.CasaluceF.MaioneP.RossiA.CiardielloF.GridelliC. (2014). Cetuximab in Advanced Non-small Cell Lung Cancer (NSCLC): the Showdown?J. Thorac. Dis.6 (6), 578–580. 10.3978/j.issn.2072-1439.2014.06.14

  • CrossRef
  • Google Scholar

• 169

  ShafabakhshR.PourhanifehM. H.MirzaeiH. R.SahebkarA.AsemiZ.MirzaeiH. (2019). Targeting Regulatory T Cells by Curcumin: A Potential for Cancer Immunotherapy. Pharmacol. Res.147, 104353. 10.1016/j.phrs.2019.104353

  • CrossRef
  • Google Scholar

• 170

  ShakibaeiM.JohnT.Schulze-TanzilG.LehmannI.MobasheriA. (2007). Suppression of NF-Κb Activation by Curcumin Leads to Inhibition of Expression of Cyclo-Oxygenase-2 and Matrix Metalloproteinase-9 in Human Articular Chondrocytes: Implications for the Treatment of Osteoarthritis. Biochem. Pharmacol.73 (9), 1434–1445. 10.1016/j.bcp.2007.01.005

  • CrossRef
  • Google Scholar

• 171

  ShakibaeiM.KraeheP.PopperB.ShayanP.GoelA.BuhrmannC.et al (2015). Curcumin Potentiates Antitumor Activity of 5-fluorouracil in a 3D Alginate Tumor Microenvironment of Colorectal Cancer. BMC Cancer15, 250. 10.1186/s12885-015-1291-0

  • CrossRef
  • Google Scholar

• 172

  ShaoZ.-M.ShenZ.-Z.LiuC.-H.SartippourM. R.GoV. L.HeberD.et al (2002). Curcumin Exerts Multiple Suppressive Effects on Human Breast Carcinoma Cells. Int. J. Cancer98 (2), 234–240. 10.1002/ijc.10183

  • CrossRef
  • Google Scholar

• 173

  SharmaK. L.BhatiaV. (2018). Gastrointestinal Cancers: Molecular Genetics and Biomarkers. Can. J. Gastroenterol. Hepatol.2018, 4513860. 10.1155/2018/4513860

  • CrossRef
  • Google Scholar

• 174

  ShenF.CaiW. S.LiJ. L.FengZ.LiuQ. C.XiaoH. Q.et al (2014). Synergism from the Combination of Ulinastatin and Curcumin Offers Greater Inhibition against Colorectal Cancer Liver Metastases via Modulating Matrix Metalloproteinase-9 and E-Cadherin Expression. Onco Targets Ther.7, 305–314. 10.2147/OTT.S57126

  • CrossRef
  • Google Scholar

• 175

  SilvaG.Teixeira LimaF.SebaV.Mendes LourençoA. L.LucasT. G.de AndradeB. V.et al (2018). Curcumin Analog CH-5 Suppresses the Proliferation, Migration, and Invasion of the Human Gastric Cancer Cell Line HGC-27. Molecules23 (2). 10.3390/molecules23020279

  • CrossRef
  • Google Scholar

• 176

  SoedaH.ShimodairaH.GamohM.AndoH.IsobeH.SutoT.et al (2014). Phase II Trial of Cetuximab Plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced And/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-Core0801). Oncology87 (1), 7–20. 10.1159/000360989

  • CrossRef
  • Google Scholar

• 177

  SoubaniO.AliA. S.LognaF.AliS.PhilipP. A.SarkarF. H. (2012). Re-expression of miR-200 by Novel Approaches Regulates the Expression of PTEN and MT1-MMP in Pancreatic Cancer. Carcinogenesis33 (8), 1563–1571. 10.1093/carcin/bgs189

  • CrossRef
  • Google Scholar

• 178

  SteegP. S. (2006). Tumor Metastasis: Mechanistic Insights and Clinical Challenges. Nat. Med.12 (8), 895–904. 10.1038/nm1469

  • CrossRef
  • Google Scholar

• 179

  StorkaA.VcelarB.KlickovicU.GouyaG.WeisshaarS.AschauerS.et al (2015). Safety, Tolerability and Pharmacokinetics of Liposomal Curcumin in Healthy Humans. Cp53 (1), 54–65. 10.5414/cp202076

  • CrossRef
  • Google Scholar

• 180

  SuC. C.ChenG. W.LinJ. G.WuL. T.ChungJ. G. (2006). Curcumin Inhibits Cell Migration of Human colon Cancer colo 205 Cells through the Inhibition of Nuclear Factor Kappa B/p65 and Down-Regulates Cyclooxygenase-2 and Matrix Metalloproteinase-2 Expressions. Anticancer Res.26 (2a), 1281–1288.

  • Google Scholar

• 181

  SubramaniR.Lopez-ValdezR.ArumugamA.NandyS.BoopalanT.LakshmanaswamyR.et al (2014). Targeting Insulin-like Growth Factor 1 Receptor Inhibits Pancreatic Cancer Growth and Metastasis. PLoS One9 (5), e97016. 10.1371/journal.pone.0097016

  • CrossRef
  • Google Scholar

• 182

  SunX.-D.LiuX.-E.HuangD.-S. (2012). Curcumin Induces Apoptosis of Triple-Negative Breast Cancer Cells by Inhibition of EGFR Expression. Mol. Med. Rep.6 (6), 1267–1270. 10.3892/mmr.2012.1103

  • CrossRef
  • Google Scholar

• 183

  SunX.-D.LiuX.-E.HuangD.-S. (2013). Curcumin Reverses the Epithelial-Mesenchymal Transition of Pancreatic Cancer Cells by Inhibiting the Hedgehog Signaling Pathway. Oncol. Rep.29 (6), 2401–2407. 10.3892/or.2013.2385

  • CrossRef
  • Google Scholar

• 184

  SunX.MaoY.WangJ.ZuL.HaoM.ChengG.et al (2014). IL-6 Secreted by Cancer-Associated Fibroblasts Induces Tamoxifen Resistance in Luminal Breast Cancer. Oncogene33 (35), 4450. 10.1038/onc.2014.158

  • CrossRef
  • Google Scholar

• 185

  SwarnakarS.GangulyK.KunduP.BanerjeeA.MaityP.SharmaA. V. (2005). Curcumin Regulates Expression and Activity of Matrix Metalloproteinases 9 and 2 during Prevention and Healing of Indomethacin-Induced Gastric Ulcer. J. Biol. Chem.280 (10), 9409–9415. 10.1074/jbc.m413398200

  • CrossRef
  • Google Scholar

• 186

  TabassumD. P.PolyakK. (2015). Tumorigenesis: it Takes a Village. Nat. Rev. Cancer15 (8), 473–483. 10.1038/nrc3971

  • CrossRef
  • Google Scholar

• 187

  TakebeN.MieleL.HarrisP. J.JeongW.BandoH.KahnM.et al (2015). Targeting Notch, Hedgehog, and Wnt Pathways in Cancer Stem Cells: Clinical Update. Nat. Rev. Clin. Oncol.12 (8), 445–464. 10.1038/nrclinonc.2015.61

  • CrossRef
  • Google Scholar

• 188

  TawadaM.HayashiS.-i.OsadaS.NakashimaS.YoshidaK. (2012). Human Gastric Cancer Organizes Neighboring Lymphatic Vessels via Recruitment of Bone Marrow-Derived Lymphatic Endothelial Progenitor Cells. J. Gastroenterol.47 (9), 1057–1060. 10.1007/s00535-012-0638-4

  • CrossRef
  • Google Scholar

• 189

  ThieryJ. P. (2002). Epithelial-mesenchymal Transitions in Tumour Progression. Nat. Rev. Cancer2 (6), 442–454. 10.1038/nrc822

  • CrossRef
  • Google Scholar

• 190

  TodenS.OkugawaY.JascurT.WodarzD.KomarovaN. L.BuhrmannC.et al (2015). Curcumin Mediates Chemosensitization to 5-fluorouracil through miRNA-Induced Suppression of Epithelial-To-Mesenchymal Transition in Chemoresistant Colorectal Cancer. Carcin36 (3), 355–367. 10.1093/carcin/bgv006

  • CrossRef
  • Google Scholar

• 191

  TongW.WangQ.SunD.SuoJ. (2016). Curcumin Suppresses colon Cancer Cell Invasion via AMPK-Induced Inhibition of NF-Κb, uPA Activator and MMP9. Oncol. Lett.12 (5), 4139–4146. 10.3892/ol.2016.5148

  • CrossRef
  • Google Scholar

• 192

  TsengR.-C.LeeS.-H.HsuH.-S.ChenB.-H.TsaiW.-C.TzaoC.et al (2010). SLIT2 Attenuation during Lung Cancer Progression Deregulates β-Catenin and E-Cadherin and Associates with Poor Prognosis. Cancer Res.70 (2), 543–551. 10.1158/0008-5472.can-09-2084

  • CrossRef
  • Google Scholar

• 193

  van BuulJ. D.VoermansC.van GelderenJ.AnthonyE. C.van der SchootC. E.HordijkP. L. (2003). Leukocyte-endothelium Interaction Promotes SDF-1-dependent Polarization of CXCR4. J. Biol. Chem.278 (32), 30302–30310. 10.1074/jbc.m304764200

  • CrossRef
  • Google Scholar

• 194

  VandercappellenJ.Van DammeJ.StruyfS. (2008). The Role of CXC Chemokines and Their Receptors in Cancer. Cancer Lett.267 (2), 226–244. 10.1016/j.canlet.2008.04.050

  • CrossRef
  • Google Scholar

• 195

  VeeraraghavanJ.NatarajanM.LagisettyP.AwasthiV.HermanT. S.AravindanN. (2011). Impact of Curcumin, Raspberry Extract, and Neem Leaf Extract on Rel Protein-Regulated Cell Death/radiosensitization in Pancreatic Cancer Cells. Pancreas40 (7), 1107–1119. 10.1097/mpa.0b013e31821f677d

  • CrossRef
  • Google Scholar

• 196

  VincentiM. P. (2001). The Matrix Metalloproteinase (MMP) and Tissue Inhibitor of Metalloproteinase (TIMP) Genes. Transcriptional and Posttranscriptional Regulation, Signal Transduction and Cell-type-specific Expression. Methods Mol. Biol.151, 121–148. 10.1385/1-59259-046-2:121

  • CrossRef
  • Google Scholar

• 197

  VincentiM. P.CoonC. I.BrinckerhoffC. E. (1998). Nuclear Factor ?B/p50 Activates an Element in the Distal Matrix Metalloproteinase 1 Promoter in Interleukin-1?-Stimulated Synovial Fibroblasts. Arthritis Rheum.41 (11), 1987–1994. 10.1002/1529-0131(199811)41:11<1987::aid-art14>3.0.co;2-8

  • CrossRef
  • Google Scholar

• 198

  WangL.-H.WuC.-F.RajasekaranN.ShinY. K. (2018). Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. Cel Physiol Biochem51 (6), 2647–2693. 10.1159/000495956

  • CrossRef
  • Google Scholar

• 199

  WangQ.QuC.XieF.ChenL.LiuL.LiangX.et al (2017). Curcumin Suppresses Epithelial-To-Mesenchymal Transition and Metastasis of Pancreatic Cancer Cells by Inhibiting Cancer-Associated Fibroblasts. Am. J. Cancer Res.7 (1), 125–133.

  • Google Scholar

• 200

  WangW. X.SunS. Z.GuoX. L.SongY. (2008). Effect of Curcumin on Invasion and Migration of Tongue Squamous Cell Carcinoma Cell Line Tca8113. Zhonghua Kou Qiang Yi Xue Za Zhi43 (2), 101–104.

  • Google Scholar

• 201

  WangX.WangQ.IvesK. L.EversB. M. (2006). Curcumin Inhibits Neurotensin-Mediated Interleukin-8 Production and Migration of HCT116 Human colon Cancer Cells. Clin. Cancer Res.12 (18), 5346–5355. 10.1158/1078-0432.ccr-06-0968

  • CrossRef
  • Google Scholar

• 202

  WangY.-J.PanM.-H.ChengA.-L.LinL.-I.HoY.-S.HsiehC.-Y.et al (1997). Stability of Curcumin in Buffer Solutions and Characterization of its Degradation Products. J. Pharm. Biomed. Anal.15 (12), 1867–1876. 10.1016/s0731-7085(96)02024-9

  • CrossRef
  • Google Scholar

• 203

  WestermarckJ.KähäriV. M. (1999). Regulation of Matrix Metalloproteinase Expression in Tumor Invasion. FASEB j.13 (8), 781–792. 10.1096/fasebj.13.8.781

  • CrossRef
  • Google Scholar

• 204

  WongK. E.et al (2019). Curcumin Nanoformulations for Colorectal Cancer: A Review. Front. Pharmacol.10, 152. 10.3389/fphar.2019.00152

  • CrossRef
  • Google Scholar

• 205

  WooM.-S.JungS.-H.KimS.-Y.HyunJ.-W.KoK.-H.KimW.-K.et al (2005). Curcumin Suppresses Phorbol Ester-Induced Matrix Metalloproteinase-9 Expression by Inhibiting the PKC to MAPK Signaling Pathways in Human Astroglioma Cells. Biochem. Biophysical Res. Commun.335 (4), 1017–1025. 10.1016/j.bbrc.2005.07.174

  • CrossRef
  • Google Scholar

• 206

  WuW.-S.WuJ.-R.HuC.-T. (2008). Signal Cross Talks for Sustained MAPK Activation and Cell Migration: the Potential Role of Reactive Oxygen Species. Cancer Metastasis Rev.27 (2), 303–314. 10.1007/s10555-008-9112-4

  • CrossRef
  • Google Scholar

• 207

  WysoczynskiM.RecaR.RatajczakJ.KuciaM.ShirvaikarN.HonczarenkoM.et al (2005). Incorporation of CXCR4 into Membrane Lipid Rafts Primes Homing-Related Responses of Hematopoietic Stem/progenitor Cells to an SDF-1 Gradient. Blood105 (1), 40–48. 10.1182/blood-2004-04-1430

  • CrossRef
  • Google Scholar

• 208

  XiaP.SongC.-L.LiuJ.-F.WangD.XuX.-Y. (2015). Prognostic Value of Circulating CD133+cells in Patients with Gastric Cancer. Cell Prolif.48 (3), 311–317. 10.1111/cpr.12175

  • CrossRef
  • Google Scholar

• 209

  YangJ.ManiS. A.DonaherJ. L.RamaswamyS.ItzyksonR. A.ComeC.et al (2004). Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis. Cell117 (7), 927–939. 10.1016/j.cell.2004.06.006

  • CrossRef
  • Google Scholar

• 210

  YangM.-H.WuM.-Z.ChiouS.-H.ChenP.-M.ChangS.-Y.LiuC.-J.et al (2008). Direct Regulation of TWIST by HIF-1α Promotes Metastasis. Nat. Cel Biol10 (3), 295–305. 10.1038/ncb1691

  • CrossRef
  • Google Scholar

• 211

  YardenY.SliwkowskiM. X. (2001). Untangling the ErbB Signalling Network. Nat. Rev. Mol. Cel Biol2 (2), 127–137. 10.1038/35052073

  • CrossRef
  • Google Scholar

• 212

  YeX.WeinbergR. A. (2015). Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cel Biol.25 (11), 675–686. 10.1016/j.tcb.2015.07.012

  • CrossRef
  • Google Scholar

• 213

  YodkeereeS.GarbisaS.LimtrakulP. (2008). Tetrahydrocurcumin Inhibits HT1080 Cell Migration and Invasion via Downregulation of MMPs and uPA1. Acta Pharmacol. Sin29 (7), 853–860. 10.1111/j.1745-7254.2008.00792.x

  • CrossRef
  • Google Scholar

• 214

  YounsM.FathyG. M. (2013). Upregulation of Extrinsic Apoptotic Pathway in Curcumin-Mediated Antiproliferative Effect on Human Pancreatic Carcinogenesis. J. Cel. Biochem.114 (12), 2654–2665. 10.1002/jcb.24612

  • CrossRef
  • Google Scholar

• 215

  YoysungnoenP.WirachwongP.BhattarakosolP.NiimiH.PatumrajS. (2006). Effects of Curcumin on Tumor Angiogenesis and Biomarkers, COX-2 and VEGF, in Hepatocellular Carcinoma Cell-Implanted Nude Mice. Clin. Hemorheol. Microcirc.34 (1-2), 109–115.

  • Google Scholar

• 216

  YueG. G.-L.KwokH.-F.LeeJ. K.-M.JiangL.WongE. C.-W.GaoS.et al (2016). Combined Therapy Using Bevacizumab and Turmeric Ethanolic Extract (With Absorbable Curcumin) Exhibited Beneficial Efficacy in colon Cancer Mice. Pharmacol. Res.111, 43–57. 10.1016/j.phrs.2016.05.025

  • CrossRef
  • Google Scholar

• 217

  YueG. G. L.ChengS.-W.YuH.XuZ.-S.LeeJ. K. M.HonP.-M.et al (2012). The Role of Turmerones on Curcumin Transportation and P-Glycoprotein Activities in Intestinal Caco-2 Cells. J. Med. Food15 (3), 242–252. 10.1089/jmf.2011.1845

  • CrossRef
  • Google Scholar

• 218

  YuenH.-F.ChuaC.-W.ChanY.-P.WongY.-C.WangX.ChanK.-W. (2007). Significance of TWIST and E-Cadherin Expression in the Metastatic Progression of Prostatic Cancer. Histopathology50 (5), 648–658. 10.1111/j.1365-2559.2007.02665.x

  • CrossRef
  • Google Scholar

• 219

  ZajchowskiL. D.RobbinsS. M. (2002). Lipid Rafts and Little Caves. Eur. J. Biochem.269 (3), 737–752. 10.1046/j.0014-2956.2001.02715.x

  • CrossRef
  • Google Scholar

• 220

  ZhangW.CuiT.LiuL.WuQ.SunL.LiL.et al (2015). Improving Anti-tumor Activity of Curcumin by Polymeric Micelles in Thermosensitive Hydrogel System in Colorectal Peritoneal Carcinomatosis Model. J. Biomed. Nanotechnol11 (7), 1173–1182. 10.1166/jbn.2015.2073

  • CrossRef
  • Google Scholar

• 221

  ZhangZ.ChenH.XuC.SongL.HuangL.LaiY.et al (2016). Curcumin Inhibits Tumor Epithelial-Mesenchymal Transition by Downregulating the Wnt Signaling Pathway and Upregulating NKD2 Expression in colon Cancer Cells. Oncol. Rep.35 (5), 2615–2623. 10.3892/or.2016.4669

  • CrossRef
  • Google Scholar

• 222

  ZhenL.FanD.YiX.CaoX.ChenD.WangL. (2014). Curcumin Inhibits Oral Squamous Cell Carcinoma Proliferation and Invasion via EGFR Signaling Pathways. Int. J. Clin. Exp. Pathol.7 (10), 6438–6446.

  • Google Scholar

• 223

  ZhengZ. H.He-yiY.Yu-jieF.Zhong-taoZ. (2020). LncRNA KCNQ1OT1 Is a Key Factor in the Reversal Effect of Curcumin on Cisplatin Resistance in the Colorectal Cancer Cells. Mol Cell Biochem.476 (7), 2575–2585. Springer.

  • Google Scholar

• 224

  ZhouY.-N.et al (2002). Expression of E-Cadherin and β-catenin in Gastric Carcinoma and its Correlation with the Clinicopathological Features and Patient Survival. Wjg8 (6), 987–993. 10.3748/wjg.v8.i6.987

  • CrossRef
  • Google Scholar

• 225

  ZhuG. H.DaiH. P.ShenQ.JiO.ZhangQ.ZhaiY. L. (2016). Curcumin Induces Apoptosis and Suppresses Invasion through MAPK and MMP Signaling in Human Monocytic Leukemia SHI-1 Cells. Pharm. Biol.54 (8), 1303–1311. 10.3109/13880209.2015.1060508

  • CrossRef
  • Google Scholar

• 226

  ZhuL.ZhangW.WangJ.LiuR. (2015). Evidence of CD90+CXCR4+ Cells as Circulating Tumor Stem Cells in Hepatocellular Carcinoma. Tumor Biol.36 (7), 5353–5360. 10.1007/s13277-015-3196-6

  • CrossRef
  • Google Scholar

• 227

  ZhugeY.XuJ. (2001). Rac1 Mediates Type I Collagen-dependent MMP-2 Activation. J. Biol. Chem.276 (19), 16248–16256. 10.1074/jbc.m010190200

  • CrossRef
  • Google Scholar